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"Not everything that counts can be counted, 
and not everything that can be counted counts." 
 
(Sign hanging in Albert Einstein's office at Princeton) 
   
   
ABSTRACT 
Nitric oxide (NO) is an important modulator of the pulmonary circulation both at 
basal state and in pulmonary hypertension. Low levels of NO are detectable in 
exhaled gas which is believed to mirror pulmonary NO formation and elimination. 
Pulmonary embolism is a disease characterised by pulmonary hypertension, and 
thereby increased afterload of the right ventricle, and by disturbed gas exchange 
which produces hypoxemia. The role of NO in acute pulmonary embolism was 
studied in two animal models. 
 
The fraction of NO in exhaled gas increased dramatically after induction of acute 
pulmonary embolisation with both gas and solid emboli. It was found that 
approximately 50% of the increased exhaled NO could be reversed by normalising the 
airway/alveolar carbon dioxide concentration, thus indicating a regulatory role of 
carbon dioxide on pulmonary NO production in this condition.  
 
Endogenous NO production exerts a protective effect in acute pulmonary embolism 
since it was found that inhibition of endogenous NO production in combination with 
pulmonary embolisation resulted in a severely augmented hemodynamic response and 
significantly impaired the survival in this condition. Therefore it was further 
hypothesised that exogenous NO might be protective in this condition. 
 
NO donor compounds, some of which were novel organic nitrites, with increased 
selectivity towards the pulmonary circulation were developed. Intravenously 
administered organic nitrites reduced the pulmonary hypertension and relieved the 
strain on the right ventricle in acute pulmonary embolism without adverse effects in 
the form of systemic hypotension, methaemoglobin formation and tolerance 
development. Methods for identification and characterisation of organic nitrites were 
described, including a novel HPLC-NO/nitrite analysis. 
 
These studies show that exhaled NO is increased after acute pulmonary embolism 
thus emerging as a potential diagnostic aid in this condition. Endogenous NO is 
protective in acute pulmonary embolism which provides further knowledge on the 
role of NO in the pulmonary circulation. Exogenous NO, in the form of certain 
organic nitrites, exerts beneficial effects in acute pulmonary embolism, thus rendering 
organic nitrites as a potential future life-saving treatment in acute pulmonary 
embolism. Future studies will investigate the effects of organic nitrites in 
experimental models of other life-threatening diseases with compromised pulmonary 
circulation.  
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Nitric oxide in experimental pulmonary embolism 
1. INTRODUCTION 
The primary function of the lung is gas exchange, i.e. saturating the haemoglobin in 
the blood with oxygen and excreting carbon dioxide produced by the cells of the body. 
Normally the pulmonary circulation is a high flow-low pressure system and the right 
ventricle is therefore adapted to pumping large volumes of blood against a low 
afterload (131). Normally the perfusion is matched to the ventilation, thus optimising 
gas exchange (131). The most important mechanism for ventilation-perfusion 
matching is hypoxic vasoconstriction, first described by von Euler & Liljestrand (240). 
Another important regulator of the pulmonary circulation is the endogenous 
pulmonary vasodilator nitric oxide (NO) which has been suggested to take part in the 
matching of ventilation and perfusion (6, 177). The present thesis investigates 
pulmonary embolism where the resistance in the pulmonary circulation is abnormally 
increased, thus challenging the right ventricle, and where the gas exchange is severely 
disturbed due to a mismatch between ventilation and perfusion resulting in hypoxemia. 
Especially the studies concerned the role of NO in experimental pulmonary embolism.  
1.1. NITRIC OXIDE 
With the discovery of endothelial-derived relaxing factor and its elucidation as 
biologically formed NO gas, two new principles were established: signalling via gas 
molecules and the role of the endothelium in vascular regulation (76, 101, 169). Since 
then a multitude of papers has been published on the role of NO in biological systems 
and the reader is referred to them. Importantly, the role of NO in vascular regulation 
in health and disease (148), its roles in the nervous system (116, 246), its diverse 
function in intracellular signalling and the immune response (77), the biological 
chemistry of NO (93) and biochemistry of NO (211, 212) have been reviewed 
elsewhere. In addition to NO formation by NO synthases (NOS), NO can also be 
produced independently of NOS from inorganic nitrite and nitrate in mammals (132). 
Phosphodiesterases, and specifically phosphodiesterase 5, play an important role in 
the biological functions of NO (73).  
1.1.1. Nitric oxide in the lung 
A fairly recent review deals extensively with the role of NO in the pulmonary system, 
including exhaled NO (189). All three isoforms of NOS are expressed in the lung (78). 
Endothelial NOS is located to the vascular endothelium, thus regulating vessel 
diameter (196), but found also in type II alveolar epithelial cells (172) and bronchial 
epithelial cells (197). Neuronal NOS is found in neurons within the lung (117), where 
it mediates nerve-induced smooth muscle relaxation (24). Pulmonary macrophages 
contain inducible NOS which produces NO in cytotoxic amounts, thereby involved in 
host defence (107) but inducible NOS can be expressed in several other non-immune 
type cells in the lung upon stimulation (19, 189). Several phosphodiesterases 
including phosphodiesterase 5 have been identified in human pulmonary artery and 
human lung (55, 186). The phosphodiesterase 5 is abundant in the lung which 
therefore makes treatment of some pulmonary diseases, e.g. primary pulmonary 
hypertension, with phosphodiesterase 5 inhibitors logical (2, 44, 182). 
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Exhaled NO 
The discovery in 1991 that NO can be measured in low levels in exhaled gas in 
humans and several animals (88) started a new research field. The NO concentration 
in exhaled breath is a result of the pulmonary NO production since NO in exhaled 
breath can still be measured after stopping the circulation (88). Exhaled NO derives 
from enzymatically produced NO since it is abolished by NOS inhibition (88). 
Therefore the level of exhaled NO can be seen as an on-line measurement of 
pulmonary NO production and elimination. Nowadays exhaled NO can be measured 
in humans with a handheld, small apparatus rendering exhaled NO as an easy, non-
invasive and fast bed-side examination (92). Measurement of exhaled NO has been 
very valuable in experimental studies including investigations of the regulation of 
pulmonary NO production by oxygen, carbon dioxide and pulmonary stretching (85, 
210). Exhaled NO has also been used for monitoring of NO formation from NO 
donors such as organic nitrates and organic nitrites (35, 98, 135, 173). In healthy 
humans, single-breath measurements of exhaled NO indicated that NO in exhaled 
breath arises from terminal and respiratory bronchioles (179). In the rabbit, a major 
part of exhaled NO originates from calcium-dependent NO synthases and in particular 
endothelial NOS (178, 233). It was early shown that exhaled NO is increased in 
humans suffering from inflammation in the airways, e.g. asthma (16, 113, 175, 180). 
In asthmatics the elevated exhaled NO is mainly derived from the lower airways (111). 
The increase in exhaled NO in asthmatics and active pulmonary sarcoidosis have been 
attributed to induction of inducible NOS since the expression of this enzyme is 
induced in inflammation by inflammatory mediators and cytokines and inhibited by 
glucocortcoid treatment (114, 153, 244). Other diseases that are associated with 
increased exhaled NO include respiratory viral infections (20), pneumonia in 
ventilated patients (7), brochiectasis (112) and active fibrosing alveolitis (170, 189). 
Chronic heart failure with pulmonary abnormalities (3, 9), pulmonary hypertension, 
cystic fibrosis and ciliary dyskinesia are associated with low exhaled NO levels (21). 
The exhaled NO levels in chronic obstructive pulmonary disease are high or normal 
and high in exacerbations (10), however concurrent smoking is interfering by 
decreasing exhaled NO values (21, 180). Endogenous NO may not be important in 
regulating the tonus of the airways in basal state, but endogenous NO is counteracting 
bronchoconstrictor stimuli, e.g. histamine and ovalbumin (163, 174). Inhaled NO 
counteracts pharmacologically induced bronchoconstriction (66). Since exhaled NO is 
increased immediately after allergen-challenge and in asthmatics (175, 180) a 
protective role of endogenous NO has been suggested but damaging effects by for 
example peroxynitrite formation cannot be excluded (213). Since pulmonary NO 
production, measured as exhaled NO, is changed in several diseases affecting the lung 
and is regulated by airway/alveolar gases the response in exhaled NO in acute 
pulmonary embolism was studied in the present thesis work.  
NO in the pulmonary circulation and in ventilation/perfusion matching 
Endogenous NO continuously regulates the pulmonary and systemic circulations in 
several species including humans and rabbits, as evidenced by NOS inhibition in 
these species which increases pulmonary and systemic vascular resistances (177, 206). 
Furthermore endogenous NO is a modulator of the hypoxic vasoconstriction and 
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pulmonary hypertension induced by a thromboxane A2 analogue, U46619 (177, 228). 
Local regulation of pulmonary blood flow is attenuated by NOS inhibition (190). 
Pulmonary NO production has been shown to be regulated by airway CO2 and O2 (6). 
Hypoxia (<10%) and hypercapnia, indicating reduced ventilation/perfusion (V/Q) 
ratio, have been shown to decrease pulmonary NO production (88, 210). Normoxia 
and hypocapnia, indicating increased V/Q ratio, have been shown to increase 
pulmonary NO production (243). The phenomenon of reciprocal changes in expired 
CO2 and NO has been shown both for hypocapnia and hypercapnia in vivo and in 
isolated lungs (29, 33, 243), however the mechanism still remains to be elucidated. It 
has been shown both in vivo in humans and animals and in isolated lungs that severe 
hypoxia (<10%) reduces exhaled NO (11, 85, 88, 100, 194). This effect is probably 
derived from that the enzymatic formation of NO involves molecular oxygen (67). 
Interestingly, hypoxia in combination with hypercapnia decreases exhaled NO even 
further (243). In addition, pulmonary stretch by increasing the functional residual 
capacity increases pulmonary NO production (210) and inhibition of stretch-
dependent calcium channels by gadolinium chloride decreases pulmonary NO 
production and induces pulmonary hypertension (5). Therefore, it has been suggested 
that endogenous NO is an important modulator of V/Q matching (6, 177, 190), but 
this has been challenged since inhalation of a NOS inhibitor decreased the ventilation-
perfusion heterogeneity in healthy dogs (29). One explanation to this discrepancy may 
be that endogenous NO does not regulate basal pulmonary vascular resistance in dogs 
(192), in contrary to in humans and rabbits (177, 206). Nevertheless, these studies 
show that endogenous NO production is an important pulmonary vasodilator both in 
health and in pulmonary hypertension; therefore it would be important to study its 
role in acute pulmonary embolism. 
1.1.2. Nitric Oxide Donors 
Nitric oxide donors are compounds that can release NO to the body and may be used 
as treatments in condition where additional NO is thought to be beneficial. Inhaled 
NO gas is special in that it is a way to deliver the actual NO molecules specifically to 
the lung and the blood that passes the lung. There are a wide range of different NO 
donors although only a few are in clinical use, and their chemistry and biological 
applications have been reviewed extensively elsewhere (231). The following text aims 
to present aspects of some clinically relevant NO donors and inhaled NO, that have 
been tested in pulmonary embolism. 
Organic nitrates 
The use of one organic nitrate, nitroglycerin, in angina pectoris was described in 1879 
as well as its similarity to the organic nitrite, amyl nitrite (161, 166). Indeed they are 
very efficient anti-anginal and anti-ischemic agents, with the advantage that they 
rarely cause coronary steal phenomenon (221). Nitroglycerin and isosorbide 
mononitrate are used in acute and chronic anginal pain respectively and nitroglycerin 
may be used in the treatment for anal fissure (149). Isosorbide dinitrate together with 
hydralazine is used for heart failure in African-Americans (149). Other uses of 
nitroglycerin include left ventricle failure, and systemic blood pressure regulation in 
acute hypertensive crisis and in controlled hypotension in surgery (166). Organic 
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nitrates are NO donor compounds that contain a C-O-NO2-group. The mechanism of 
action is due to the release of NO, as shown in vivo by the use of exhaled NO (13, 98, 
173), and the vasodilation is exerted via activation of soluble guanylate cyclase (18, 
159). Several enzymes have been suggested to take part in the bioactivation of 
nitroglycerin and other organic nitrates, but hitherto the most convincing suggestion is 
mitochondrial aldehyde dehydrogenase (38). Interestingly, mice lacking the gene for 
this enzyme are partly resistant to nitroglycerin, but still responsive to higher doses 
(100 times) indicating the existence of high affinity and low affinity bioactivation 
pathways (37). Still the NO species that arise from bioactivation and activate 
guanylate cyclase are elusive, e.g. NO, inorganic nitrite or others (139). A significant 
clinical problem with organic nitrates is the rapid tolerance development 
(tachyphylaxis), especially in intravenous nitroglycerin treatment which can be 
studied experimentally (14, 23, 98, 220). There is also cross-tachyphylaxis between 
several organic nitrates (13). Probably the tolerance to nitroglycerin is due to 
decreased bioactivation or bioavailability of nitroglycerin-derived NO or a related 
species, consistent with the findings that nitroglycerin-tolerant rabbits show decreased 
NO generation in exhaled gas from nitroglycerin (13, 14). Several hypotheses 
regarding the tolerance development have been proposed, including the oxidative 
stress hypothesis meaning that nitroglycerin-derived NO bioavailability is reduced 
due to the reaction with superoxide (139). The vascular thiol depletion hypothesis is 
based on the interpretation that nitroglycerin is bioactived by thiols and that 
nitroglycerin consumes the thiols in the cell thus limiting its own bioactivation (139). 
Interestingly, mice that lack mitochondrial aldehyde dehydrogenase, and therefore 
bioactivate nitroglycerin by the low affinity pathway, and wild type nitroglycerin-
tolerant mice respond similarly to nitroglycerin, indicating that tolerance is due to 
inactivation of the high-affinity bioactivation pathway (37). It is suggested that 
bioactivation renders the mitochondrial aldehyde dehydrogenase in an inactive state 
and that the enzyme needs to be reduced to its initial state by a reducing agent, which 
may be depleted thus explaining the thiol-depletion hypothesis and the beneficial 
effects of antioxidants in nitroglycerin-induced tolerance (139). Therefore by using 
NO donors that do not need this bioactivation step or possibly utilise another enzyme 
system for their activation, tolerance development may be avoided.  
Organic nitrites 
The use of one organic nitrite, amyl nitrite, in angina pectoris was first described in 
1867 (30), but amyl nitrite was later replaced by nitroglycerin due to its longer 
duration of action (161, 166). Nowadays inhaled amyl nitrite is sometimes used as an 
antidote in life-threatening cyanide intoxication (127). In contrast to organic nitrates, 
organic nitrites exhibit little or no tolerance in vivo and in vitro and do not have 
substantial cross-tachyphylaxis with organic nitrates (23, 122). In healthy humans 
inhaled amyl nitrite produces a very rapid (within 15-20 s) systemic hypotension and 
reflex tachycardia (154). Inhaled amyl nitrite has shown beneficial effects in a porcine 
model of pharmacologically induced acute catastrophic pulmonary hypertension, but 
methaemoglobin was not measured (158). Inhaled ethyl nitrite has even been 
suggested as an inhaled therapeutic in newborns with persistent pulmonary 
hypertension, however methaemoglobin concentration increased to 3.2% (mean) after 
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4 hours of treatment and up to 8% in one newborn (156). It is suggested that inhaled 
ethyl nitrite is effective in reacting with and replenishing S-nitrosothiols and therefore 
more beneficial compared with inhaled NO in reducing pulmonary vascular resistance 
in a porcine model of pulmonary hypertension, however methaemoglobin may have 
reached 2% (157). These data show that organic nitrites are potent vasodilators with 
rapid on-set both in the pulmonary and systemic circulations where, seemingly, 
inhaled ethyl nitrite is more selective for the pulmonary circulation. The use of 
organic nitrites are associated with adverse effects and, specifically, the long-term use 
of ethyl nitrite and other organic nitrites has been questioned due to the significant 
methaemoglobin formation (1, 127). Other problems with organic nitrites are 
development of internal pressure in ampoules (“poppers”) and degradation during 
dilution, problems which are solved in the present thesis work. Organic nitrites are 
compounds that contain the C-O-N=O-group. The mechanism of action of organic 
nitrites are thought to be due to the release of NO and it has been demonstrated by 
using exhaled NO that organic nitrites are converted to NO in vivo (35). It has been 
suggested that cytosolic enzymes bioactivate organic nitrites (122). In particular, 
glutathione transferases have been shown to catalyse the formation of S-
nitrosoglutathione from organic nitrites (15, 105, 147), which may be a step in its 
bioactivation. Interestingly lung, heart and liver in rats show the highest capacity of 
enzymatic formation of S-nitrosoglutathione from organic nitrites (15). It has also 
been suggested that xanthine oxidase reduces organic nitrites to NO in anaerobic 
conditions (63). Taken together, organic nitrites may be useful NO donors due to their 
rapid onset, absence of tolerance development and high abundance of enzymatic 
activity in lung and heart, tissues which may be primary targets for therapy. 
Methaemoglobin is probably the most detrimental adverse effect and should therefore 
be monitored.  
There are several methods for producing organic nitrites, including reaction of 
alcohols with nitrous acid or other nitrosating agents such as nitrosyl chloride and 
nitrosonium salts (167, 238) or nitrosyl exchange between an alcohol and an alkyl 
nitrite (65). Grossi & Strazzari (86) produced cycloalkyl nitrites from the reaction of 
NO gas with parent cycloalkyl alcohols in the presence of oxygen. They suggested 
that the reaction in this situation is not through the NO molecule itself but rather from 
nitrous anhydride (N2O3), a known nitrosating agent, which is formed in the reaction 
between NO and molecular oxygen (4 NO + O2 Æ 2 N2O3). The present thesis work 
introduces a method involving usage of pure nitric oxide gas for producing stable 
aqueous solutions of organic nitrites suitable for intravenous infusion.  
Sodium nitroprusside 
Intravenous infusions of sodium nitroprusside have since long been used to reduce 
systemic arterial blood pressure in hypertensive crises since it is a powerful 
vasodilator (232). However it is associated with tolerance development (232). Sodium 
nitroprusside is a metal-NO complex (231). In solution it is extremely sensitive to 
light and decomposes rapidly (231). The bioactivation of sodium nitroprusside is not 
fully understood and may be both enzymatic and non-enzymatic but it involves 
release of cyanide (231). Therefore it is associated with risk of cyanide intoxication 
and its use is sometimes discouraged (232). 
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Inhaled NO 
Administering vasodilators as inhalations are one option to try to confine the 
vasodilatory effects within the pulmonary circulation. The hemodynamic effects of 
inhaled NO are specific to the pulmonary circulation and it is effective in 
counteracting pulmonary hypertension (74) although it may also have other 
potentially beneficial systemic effects (48). Another important feature with inhaled 
NO is that it will increase perfusion in well-ventilated lung parts, thereby potentially 
improving arterial oxygenation (181). Inhaled NO is used in persistent pulmonary 
hypertension of the newborn (41) whereas use of inhaled NO in acute lung injury and 
acute respiratory distress syndrome is not recommended (8). The site of pulmonary 
vasodilation by inhaled NO has been estimated to smaller arteries and veins in 
contrast to an intravenous NO donor that also affects larger vessels in the lung (146, 
191). Interestingly, it has been suggested that inhaled NO reaches the pulmonary 
vasculature to a smaller degree in non-responders of newborns with persistent 
pulmonary hypertension compared with responders (168). Nevertheless, inhaled NO 
is a very efficient therapy in some pulmonary diseases but in others it may not be 
effective since it may not reach upstream targets in the pulmonary circulation. In these 
cases an intravenous lung-selective NO donor would be preferable.  
Inorganic nitrite 
Inorganic nitrite when infused intravenously can at high infusion rates lead to NO 
donation in the lungs as evidenced from measurements of exhaled NO (12) and 
inorganic nitrite is a potential NO donor in a multitude of situations (132). Indeed, 
inorganic nitrite has been shown to be a vasodilator in the pulmonary circulation (57) 
and therefore comparisons between inorganic nitrite and organic nitrite NO donation 
are relevant and will be made in the present work. 
1.2. PULMONARY EMBOLISM 
1.2.1. Epidemiology of pulmonary embolism 
Pulmonary embolism is a complication of deep venous thrombosis, and these diseases 
are grouped as venous thromboembolism. Venous thromboembolism is a common 
disease affecting both sexes, with an annual incidence of 0.7-1.1 per 1000 in the 
general Caucasian population (199, 236). Pulmonary embolism is evident in one third 
to one half of the total cases of venous thromboembolism (236). The prevalence of 
acute pulmonary embolism in hospitalized patients has been estimated to 1% (207). 
Pulmonary embolism may be a complication to malignancies and other chronic 
diseases, but it will also occur frequently in conditions that may strike otherwise 
healthy people in working age and importantly the incidence of venous 
thromboembolism increases exponentially as early as after the age of 40 (17, 199, 
236).  
1.2.2. Diagnosis of acute pulmonary embolism 
The symptoms of pulmonary embolism are dyspnea, chest pain, palpitations, syncope, 
cough and haemoptysis (82, 151, 208). The signs of pulmonary embolism are 
tachycardia, crackles, unilateral leg swelling, cyanosis and neck vein distension (151, 
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208). Both the symptoms and signs of pulmonary embolism are non-specific with 
several differential diagnoses, thus making pulmonary embolism a true diagnostic 
challenge (151, 208). Normally, but not exclusively, pulmonary embolism is 
associated with arterial hypoxemia, and hypocapnia due to hyperventilation (151, 
208). Simple prediction models such as Wells’ score (235) or the revised Geneva 
score (128) can be used clinically to approximate the probability for pulmonary 
embolism and thus to estimate the need for further investigations (224). D-dimer may 
be used together with clinical prediction models to exclude PE but due to its low 
positive predictive value increased D-dimer is not specific enough (224). Multi-
detector computed tomography is nowadays becoming a standalone investigation both 
for excluding and confirming pulmonary embolism, which is accurate if the clinical 
probability of pulmonary embolism is concordant (224). Right ventricle 
echocardiography can be used to monitor the degree of right ventricular dysfunction 
(82, 224). The European Society of Cardiology’s guidelines suggest, that in suspected 
pulmonary embolism with systemic hypotension and/or shock, computed tomography 
should be performed immediately if possible (224). In suspected pulmonary embolism 
with stable hemodynamics, the guidelines suggest that the susceptibility should be 
estimated (with e.g. Wells’ score) and in the cases where the susceptibility is low, a 
negative D-dimer excludes pulmonary embolism (224). If the D-dimer is positive or 
the susceptibility of pulmonary embolism is high, a multi-detector computed 
tomography should be performed (224). Despite the use of these algorithms, more 
than 50% of the patients that are investigated with multi-detector computed 
tomography will actually not have pulmonary embolism (235), meaning that 
approximately 50% of the computed tomographies performed are strictly speaking not 
necessary. They will find other diseases, e.g. pulmonary oedema due to left heart 
failure or pneumonia, and may therefore be of value in explaining the patient’s 
symptoms, but these diagnoses do not require computed tomography, instead chest X-
rays are sufficient. Therefore, in order to reduce the number of expensive and time-
consuming investigations with computed tomography, it would be of great value to 
improve these clinical prediction models with new markers of acute pulmonary 
embolism. In the present thesis work, it was investigated in experimental models of 
acute pulmonary embolism if exhaled NO may be a marker identifying embolism.  
1.2.3. Outcome and risk stratification in acute pulmonary embolism 
At presentation, most patients with pulmonary embolism are symptomatic and 
hemodynamically stable, whereas approximately 5-10% are in shock (82, 110). 
Although hemodynamically stable, almost 50% show signs of right ventricular 
dysfunction, which is a strong predictor of poor outcome probably because 10% 
develop shock later (82, 110, 119, 124). Normally right ventricular dysfunction is 
determined with transthoracic echocardiography but it may also be estimated with 
multi-detector computed tomography or laboratory tests such as cardiac troponins and 
natriuretic peptides (i.e. N-terminal-probrain natriuretic peptide and brain natriuretic 
peptide), however the laboratory tests must be interpreted carefully due to the low 
specificity (119, 124). The overall 30 day mortality of treated pulmonary embolism 
cases is estimated to approximately 12% (236), but the majority of deaths is in non-
diagnosed cases (49). Ten percent of symptomatic pulmonary embolism cases are 
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fatal within the first hours (110), which accounts for two thirds of the mortality in 
recognised pulmonary embolism (241). The 3-months mortality in hemodynamically 
stable patients may be 10-15% and in hemodynamically un-stable patients up to 25-50% 
(82, 110, 241). This further strengthens the need of new and fast methods in 
pulmonary embolism diagnosis, the need to initiate treatment immediately and the 
need for new treatment methods. In order to improve the risk prediction of mortality 
in pulmonary embolism and to identify patients that need intensive treatment, several 
scoring systems, using easily available clinical data and routine laboratory tests, have 
been developed (224). In the guidelines of the European Society of Cardiology on 
pulmonary embolism it is suggested that the presence of systemic hypotension 
decides if the patient is of high risk (>15% early mortality) or of non-high risk (early 
mortality 0-15%) of early mortality (224). In the non-high risk group, an intermediate 
risk group (early mortality of 3-15%) is identified on the basis of right ventricular 
dysfunction (either by echocardiography or biochemical) and/or myocardial ischemia 
(biochemical markers) (224). Nevertheless, there is a clinical need for new markers 
that estimate the severity of pulmonary embolism that can be used in combination 
with the present markers in order to facilitate the decision on treatment with e.g. 
thrombolysis in acute pulmonary embolism. In the present thesis, it was investigated 
in experimental models of acute pulmonary embolism if exhaled NO may be a marker 
of severity of the disease. 
1.2.4. Treatment of acute pulmonary embolism 
The treatments of acute pulmonary embolism include hemodynamic and respiratory 
support, thrombolysis, surgical embolectomy, percutaneous catheter embolectomy 
and fragmentation and anticoagulation, depending on the severity of the pulmonary 
embolism (224). The guidelines suggest that patients in the high risk group should be 
treated with thrombolysis, if no absolute contraindications are present (risk of major 
bleeding), due to a significant reduction of death and recurrent pulmonary embolism 
in these patients (224, 230). Initially, hemodynamic and respiratory support may be a 
major part of the treatment in these patients (224). Surgical (preferred) or 
percutaneous catheter (second choice) embolectomies can be performed in high-risk 
patients if there are absolute contraindications to thrombolysis or if thrombolysis fails 
to improve hemodynamics (224). In patients with low risk of in-hospital death 
treatment with anticoagulation is sufficient (224). Major bleeding, e.g. intracranial 
hemorrhage, the feared complication of the treatment, is more frequent in patients 
treated with thrombolysis compared to anticoagulation (82) and happens in 
approximately 13% of patients treated with thrombolysis (224). Therefore it is always 
a risk-benefit situation for the individual patient when deciding on whether to treat 
with anticoagulation or thrombolysis. Still there is uncertainty about which patients in 
the intermediate-risk group that will actually benefit from more intensive treatments 
(e.g. thrombolysis). It has been suggested that thrombolysis should be considered in 
hemodynamically stable patients with right ventricular dysfunction shown by 
echocardiography and raised cardiac troponins or natriuretic peptides, however no 
such clinical study exists at present (119, 124-126). New markers for risk 
stratification of disease severity may help in this decision.  
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1.2.5. Pathophysiology of acute pulmonary embolism 
The pathophysiology of acute pulmonary embolism is pulmonary hypertension and 
gas exchange disturbances, with risk of right ventricular failure, circulatory collapse 
and death.  
Pulmonary gas embolism is a special form of acute pulmonary embolisation and 
although the cause and treatment differ significantly from pulmonary embolism with 
solid emboli, the pathophysiology is rather similar (204). Pulmonary gas embolism 
also produces the pathological consequences that will be discussed below, but one 
important difference exists, it will resolve by itself within approximately 30 min (94).  
Pulmonary hypertension 
The pulmonary hypertension in pulmonary embolism results from both mechanical 
obstruction and pulmonary vasoconstriction (200, 209), although the balance between 
them remains to be established. There are several evidences that pulmonary 
vasoconstriction is important: Mechanical occlusion of the blood flow to one lung 
(50%) by an intravascular balloon does not increase the pulmonary arterial pressure as 
much as embolization of a smaller part of the lung (28, 108, 141). In previously 
healthy humans suffering from acute pulmonary embolism, vascular obstruction 
above 25-30% increases mean pulmonary arterial pressure above 20 mmHg and if the 
obstruction reaches 50% the mean pulmonary arterial pressure exceeds 35 mmHg 
(140, 141). Although significant, poor correlations were found between the extent of 
angiographic vascular obstruction and pulmonary arterial pressure and arterial partial 
pressure of oxygen in acute pulmonary embolism (140, 141). In hemodynamically 
stable patients with moderate pulmonary embolism, the right ventricular dysfunction 
does not correlate well to perfusion abnormalities in the lung (150). In cross-
circulatory experiments in sheep, a transmissible factor from the animal suffering 
from acute pulmonary embolism induced pulmonary hypertension, decreased lung 
compliance and caused hyperventilation in the recipient sheep (91). Platelets are key 
players in acute pulmonary embolism, as they are activated on the pulmonary emboli 
and subsequently release several vasoconstrictors and other substances (40, 202, 223). 
The most important vasoconstrictors in acute pulmonary embolism are thought to be 
serotonin, thromboxane A2  and endothelin-1 (22, 188, 193, 227). It was suggested 
already 50 years ago that pulmonary vasoconstriction, induced by serotonin release 
from platelets, contributes to the hemodynamic response in acute pulmonary 
embolism (43). Serotonin is released immediately after experimental pulmonary 
embolisation and is suggested to mediate part of the pulmonary hypertension in acute 
pulmonary embolism (227). In a rabbit model of acute pulmonary embolism, 
thromboxane A2 was released immediately after embolisation and the level of 
increase correlated with risk of early mortality (188). In a canine model of acute 
pulmonary embolism, thromboxane A2 was released and pretreatment with a 
thomboxane synthesis inhibitor abated the cardiopulmonary effects of acute 
pulmonary embolism (226). In pulmonary embolism endothelin-1 is released from 
several cells including the injured pulmonary endothelium (22). In humans suffering 
from pulmonary embolism and in a sheep model of pulmonary gas embolism levels of 
endothelin-1 were increased and in the animal model endothelin receptor antagonism 
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partly decreased the pulmonary hypertension (152, 203). There are also other 
potential vasoconstrictive mediators, although the roles of these are less defined in 
acute pulmonary embolism (e.g. adenosine diphosphate, platelet-derived growth 
factor, platelet-activating factor, angiotensin II, histamine and thrombin) (209).  
The gas exchange disturbances in acute pulmonary embolism 
The gas exchange disturbance seen in acute pulmonary embolism is characterised by 
four changes. First, there is an increase in high V/Q ratios and in dead-space 
ventilation due to mechanical obstruction of blood flow and pulmonary 
vasoconstriction (31, 50, 81, 102). Second, there is an increase in low V/Q ratios due 
to the redistribution of blood flow from obstructed parts of the lung to perfused parts 
of the lung (50, 81, 102). Third, a true shunt may develop as a result of atelectases 
caused by loss of surfactant or hemorrhage (50). Fourth, as a result of the two first 
changes, normal V/Q ratios are decreased (81, 102). In addition, the work of breathing 
may be increased due to bronchoconstriction, probably caused by mediators released 
from platelets (68, 87, 222) and due to decreased compliance of the lung (42, 68). 
The resultant arterial hypoxemia is caused by several factors: 1) The most important 
reason is the development of areas with low V/Q ratios meaning that the ventilation is 
not enough to fully saturate the blood flow (50, 81). 2) The development of a true 
shunt, i.e. venous blood mixes with arterial blood without passing ventilated parts of 
the lung, will severely affect arterial oxygenation (47, 68). The true shunt may be 
intra-cardiac, most commonly through a patent foramen ovale, or it may be 
intrapulmonary, in areas of atelectases caused by loss of surfactant or hemorrhage 
(68). Increasing inhaled oxygen concentration will not improve arterial saturation in 
patients with a true shunt (68). 3) If cardiac output decreases, the oxygen extraction in 
systemic tissues will increase to maintain normal oxygen uptake (68, 81). This will 
further deteriorate arterial hypoxemia by enhancing the effect of the two first causes 
(81).  
Right ventricular dysfunction in acute pulmonary embolism 
In acute pulmonary embolism, the pulmonary hypertension in combination with the 
arterial hypoxaemia constitute a major threat to the right ventricle and the survival of 
the patient. In previously healthy patients suffering from acute pulmonary embolism, 
the mean pulmonary arterial pressure never exceeds 40 mmHg since the pulmonary 
circulation normally is a low pressure-high flow circulation (142). Normally the right 
myocardium is perfused during both systole and diastole since the systemic arterial 
blood pressure (120/80 mmHg) is higher than the systolic right ventricle pressure (20-
25 mmHg) throughout the cycle (34, 237). In severe pulmonary hypertension, when 
the right ventricular and the right atrial pressures are increased, the perfusion of the 
right ventricular myocardium will be more dependent on the diastolic systemic 
arterial pressure and take place mostly during diastole. Systemic hypotension either as 
a result of the disease state itself or from vasodilator therapy will further limit 
perfusion of the right myocardium, thus increasing the risk of ischemia (237). In 
severe pulmonary hypertension, the systole of the right ventricle will have longer 
duration resulting in that the diastolic phase of the left ventricle starts before the 
systolic phase of the right ventricle ends. This provokes a leftward movement of the 
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septum and then when the left ventricle contracts in systole the septum moves 
rightwards, known as septal dyskinesia (34, 104, 237). If acute cor pulmonale 
develops (a dilated right ventricle), the increased volume in the right ventricle will 
provoke even more bulging of the septum into the left ventricle, which restricts the 
filling of the left ventricle in diastole (25, 104). As a consequence of septal dyskinesia 
and the impaired filling of the left ventricle, the left heart function is impaired which 
may result in systemic hypotension and decreased cardiac output (25, 34, 237). Severe 
dilatation of the right ventricle may also result in tricuspid regurgitation, which may 
decrease cardiac output even further (34, 237). The changes in right and left heart 
function is restored after successful treatment (104). 
1.2.6. Vasodilator therapy in acute pulmonary embolism 
Since relieving the afterload of the right ventricle is essential, i.e. decreasing the 
pulmonary hypertension, in acute pulmonary hypertension several vasodilator 
strategies have been investigated in experimental models of acute pulmonary 
embolism and in a few small studies or case reports in humans (200). Vasodilator 
therapy in acute pulmonary embolism must fulfil several criteria: 1) preferentially be 
a pulmonary vasodilator and not induce systemic hypotension since that will decrease 
the oxygenation of the right heart; 2) maintain normal cardiac output, increase blood 
flow in partly obstructed well-ventilated lung parts and therefore decrease blood flow 
in lung parts with low V/Q ratios, in order to maintain or improve pulmonary gas 
exchange; 3) decrease the oxygen consumption of the right heart. When considering 
the vast range of vasoconstrictors involved or potentially involved in acute pulmonary 
embolism, solely receptor antagonist treatment of one constrictor should not be 
expected to be sufficient. Therefore the present thesis work concentrated on 
investigating vasodilator compounds in pulmonary embolism. 
Intravenous vasodilators 
In the first randomised controlled trial of vasodilator treatment in humans suffering 
from acute pulmonary embolisation, prostaglandin I2 infusion intravenously did not 
decrease right ventricle dysfunction or affect the increased pulmonary arterial 
pressure (121). In contrast, in pulmonary embolisation with autologous blood clots in 
dogs, prostaglandin I2 decreased pulmonary hypertension and improved gas exchange 
paralleled with a reduction of systemic arterial blood pressure by 30 mmHg (226). In 
a porcine model of pulmonary microembolism nitroglycerin and sodium nitroprusside 
intravenously had some effects on the increase in pulmonary vascular resistance but 
they decreased the systemic vascular resistance relatively more (143). In contrast to 
prostaglandin E1 that showed better selectivity towards the pulmonary circulation but 
increased the shunt fraction. Hydralazine showed even more selectivity towards the 
systemic circulation than nitroglycerin and nitroprusside (143). In a canine model of 
acute pulmonary embolism, nitroglycerin (in a 10-fold lower dose) did not affect 
pulmonary and systemic vascular resistances but impaired the gas exchange (183). In 
a lamb model of pulmonary gas embolisation, nitroprusside had moderate beneficial 
effects on pulmonary vascular resistance but the vasodilatory effects were more 
pronounced in the systemic circulation (72). In a canine model of pulmonary 
embolisation with autologous blood clots, hydralazine and nitroprusside decreased 
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pulmonary vascular resistance however the effect on systemic circulation was larger 
whereas prostaglandin E1 only induced systemic hypotension (52). In 10 humans 
suffering from pulmonary embolism intravenous infusion of ketanserin (a serotonin 
receptor 2 antagonist) slightly decreased pulmonary arterial pressure and pulmonary 
vascular resistance (-16%), together with a 10% reduction in systemic vascular 
resistance (96). The modest effect of the serotonin antagonist may be explained by the 
delay between the pulmonary embolisation and the trial (1-13 days) and that in the 
human pulmonary circulation it is the serotonin receptor 1D that triggers 
vasoconstriction (133). In dogs where the lungs were embolised with blood clots, 
ketanserin decreased the pulmonary hypertension and improved gas exchange without 
untoward systemic affection (99). These studies show that NO donors and other 
vasodilators are able to dilate the pulmonary circulation after pulmonary embolism, 
thus further strengthening the belief that active pulmonary vasoconstriction is part of 
the pathophysiology of pulmonary embolism, even in humans. They also show that 
intravenous vasodilators are associated with risks of systemic hypotension and 
worsening of pulmonary gas exchange and that creating intravenous vasodilators with 
specificity to the pulmonary circulation may be a challenge.  
Inhaled agents 
Inhaled prostaglandin I2 in a human suffering from massive pulmonary embolism 
slightly decreased the pulmonary hypertension and improved pulmonary gas 
exchange (234). The use of inhaled NO (5-50 ppm) in humans suffering from massive 
pulmonary embolism has been described in a few case reports and shows mostly 
moderate decreases in pulmonary hypertension and improved pulmonary gas 
exchange (214, 219). In pulmonary microembolism in dogs inhaled NO (50 ppm) 
attenuated the increase in pulmonary vascular resistance by 40% and slightly 
improved pulmonary gas exchange, whereas inhaled prostaglandin I2 had no effects 
(248). In a porcine model of acute massive pulmonary microembolism, inhaled NO 
(5-80 ppm) reduced by 25% the increase in pulmonary vascular resistance and 
decreased platelet aggregation in the lung, without improving pulmonary gas 
exchange (27, 84). In pulmonary gas embolism in dogs, NO inhalation (3 ppm) 
lowered 25% of the increase in pulmonary vascular resistance and decreased the 
release of thomboxane A2, whereas inhaled NO of 40 ppm did not have any additional 
effect, however gas exchange was slightly impaired (218). In a canine model of 
autologous clot embolisation, the combination of inhaled NO (40 ppm) with an 
endothelin receptor A antagonist was only slightly more beneficial than inhaled NO 
alone (129). These studies show that especially inhaled NO in acute pulmonary 
embolisation attenuates part (up to 40%) of the increase in pulmonary vascular 
resistance without systemic hypotension; however the effects on pulmonary gas 
exchange were conflicting. In the present thesis work it is suggested that more than 40% 
of the pulmonary hypertension may be reversed by a selective intravenous pulmonary 
vasodilator, since the intravenous administration allows the NO donation to reach 
larger vessels that might dominate in the vasoconstrictive process.  
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1.3. NITRIC OXIDE IN PULMONARY EMBOLISM 
Before this thesis project was initiated it was known that fatal venous gas infusions 
increased exhaled NO (88), that pulmonary gas embolism in hemodiluted animals 
resulted in increased expired NO output (51), and that wedging of a pulmonary 
catheter and thus obstructing the blood flow increased exhaled NO from these parts of 
the lung (71).  
It was known that NO-synthase inhibition augmented platelet aggregation induced by 
adenosine diphosphate, platelet-activating factor or thrombin (138), reduced the dose 
of collagen+adrenalin required to induce thromboembolic mortality , increased bubble 
formation after decompression and reduced survival in decompressed rats (239). 
Furthermore it was known that treatment of acute pulmonary embolism with 
intravenous NO donors (e.g. nitroglycerin and nitroprusside) induces systemic 
hypotension thus limiting its use in this condition (72, 143). Inhaled NO showed 
promising but moderate effects on the pulmonary hypertension in acute pulmonary 
hypertension without inducing systemic hypotension. In contrast treatment with L-
arginine in acute pulmonary embolism was not beneficial (205).  
 
 
Aims 
2. AIMS  
 
The overall aim of this thesis was to investigate the role of NO formation in 
pulmonary vascular regulation, especially during acute pulmonary embolism.  
 
More specifically, the studies aimed to: 
 
1. Investigate in what direction NO changes during acute pulmonary embolism 
and whether it relates to changes in other respiratory gases, especially carbon 
dioxide. 
 
2. Investigate whether endogenous NO has salutatory or damaging functions 
during acute pulmonary embolism by studying the effects of NO synthase 
inhibition on pulmonary embolism. 
 
3. Find means of identifying lung selective intravenous NO donors, in order to 
obtain efficient pulmonary vasodilation in situations with compromised 
pulmonary circulation. 
 
4. Investigate the effects of intravenous lung selective NO donors in acute 
pulmonary embolism. 
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3. METHODS 
The present thesis work employed rabbit in vivo models of experimental pulmonary 
hypertension and pulmonary embolism in order to investigate the role and response of 
endogenous NO and to investigate the therapeutic potential of new NO donors, in 
these conditions. A rabbit in vivo bioassay model was used for determining in vivo 
NO donating capabilities and selectivity of NO donor solutions. A new production 
method for producing solutions of new NO donating organic nitrites suitable for 
intravenous infusions was invented. A method where HPLC was connected to on-line 
detection and quantification of inorganic and organic nitrites was developed. Gas 
chromatography-mass spectrometry (GC-MS) was used for chemical identification of 
some new organic nitrites. Molecular properties of the used organic nitrites were 
calculated and were used in order to understand critical properties of the individual 
organic nitrite molecules for selectivity towards the pulmonary and systemic 
circulation respectively. For a detailed description of the methodology used in this 
thesis work, please refer to the individual paper. 
3.1. NO DONOR SOLUTIONS 
3.1.1. Preparation of NO donor solutions for intravenous infusions and 
chemical characterisation (Paper III, IV) 
Aqueous solutions of alcohols and sugars and related compounds (Table 1), saline and 
a lipid emulsion were prepared and placed in gas tight cylinders (volume 20-150 ml) 
with taps in both ends and a sideway port with a septum plug in the middle portion. 
The cylinders were filled to 75% with solution, allowing a gaseous head-space. The 
solutions were deoxygenated by means of helium bubbling for 10 min and purged 
with pure nitric oxide gas for 3-5 min. From the gas-tight cylinders the solutions were 
transferred via the side port septum plug to syringes for i.v. infusions in rabbits for 
determination of NO donating capabilities. Samples were also analysed by GC-MS 
for chemical identification, and either directly in a nitrite reduction system or in 
HPLC coupled to nitrite reduction for NO donating capability and for quantification 
of the content of NO gas and inorganic and organic nitrites.  
3.1.2. HPLC coupled to on-line measurement of NO/nitrites by 
chemiluminescence (Paper III, IV) 
Samples of NO donor solutions were analysed in HPLC, HPLC coupled to on-line 
measurements of NO/nitrites (denoted LC-NO) and directly in the nitrite reduction 
system with or without reducing agent.  
The HPLC system 
The HPLC consisted of equipments stated in paper III and IV and in Nilsson et al. 
(165). Briefly, a reverse phase HPLC was used, with analytical C18 or CN columns 
eluted either in isocratic mode (5-10 mM ammonium formate in water with 0-8% of 
acetonitrile) or with a linear gradient (from 5-10 mM ammonium formate in water 
followed by increasing proportions [3%/min] of methanol or acetonitrile) at flow rates 
of 0.5-1.0 ml min-1 depending on the size of the column. The UV absorbance during 
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elution was measured with a variable UV absorbance detector at 227 nm or 254 nm 
and a scanning UV absorbance detector (190 – 370 nm). Pumps were controlled and 
UV absorbance measurements were collected by commercial hardware and software. 
The volume of the injector loop was 2.2 ml and samples, nitrite standards and 
commercially available organic nitrites were injected at volumes of 2 µl - 2 ml. In 
some experiments in order to enrich the compounds of interest for GC-MS, repeated 
injections were performed when the retention times of these compounds allowed. The 
effluent from the HPLC system could then either be collected in gas tight syringes for 
GC-MS or continuously be introduced into a nitrite reduction system for on-line 
measurement of NO/inorganic nitrite/organic nitrites by means of a 1/16 inch 
PolyEtherEtherKetone (PEEK) capillary. 
On-line measurement of NO/inorganic nitrite/organic nitrite by chemiluminescence  
The NO/nitrites analysis utilised a similar system as in Hallén et al. (90), based on the 
method by Walters et al. (229). Inorganic and organic nitrites are reduced to NO in 
this environment whereas nitrates are not reduced (229). Aliquots or the effluent from 
the HPLC were intermittently respectively continuously injected in a temperature-
controlled reaction chamber (total volume 300 ml) containing 75 ml of 1% (w/v) 
sodium iodide in hot (89° C) glacial acetic acid. In some experiments the reducing 
agent was replaced by ultra-pure water in order to measure the content of NO gas in 
the samples. The reaction solution was purged with N2-gas (150-200 ml min-1) to 
deoxygenate the solution and to carry NO gas to a chemiluminescence NO analyser 
system. In the NO analyser ozone was produced in an oxygen flow of 100 ml min-1 
and made to react in a vacuum chamber with the NO in the incoming gas from the 
reducing chamber (sample flow rate 150-200 ml min-1). The signal from the 
photomultiplier tube was collected by a computerised data acquisition system. The 
system was intermittently calibrated with aliquots (10-500 µl) of known amounts of 
sodium nitrite either by direct injection or via the HPLC system (detection limits: 5 
pmol and 10 pmol respectively). When only measuring NO gas with the system, it 
was calibrated by direct injections of known amounts of NO gas in nitrogen. The 
sensitivity of the photomultiplier tube was adjusted in order to measure in the linear 
range. In experiments where the HPLC effluent was introduced into the reaction 
chamber, the volume in the reaction chamber increased slowly and intermittent 
withdrawal and refurbishment of liquid was necessary. In order to minimise the 
interference of different volumes in the chamber, calibration was always done before 
and after each analysis. These calibrations were very similar and the mean between 
the two sets was used in the calculation of quantity. Quantification of NO content was 
made by comparing peak area measurements with the peak area of a known amount of 
standard. The recovery of the LC-NO system was 88-100%. 
3.1.3. Gas chromatography-mass spectrometry (Paper III) 
Eluted peaks from the HPLC with the reaction mixture of propanol and NO gas were 
collected in gas tight syringes and extracted by an equal volume of toluene if 
necessary. Alternatively, samples of 25-100 % propanol and NO gas and samples of 
commercial propyl nitrite (for comparisons) diluted in toluene were injected directly 
in the gas chromatography column thus bypassing the extraction procedure. Fractions 
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were injected at 1 µl onto an Agilent DB-5MS gas chromatography column (0.25 mm 
i.d., 30 m length, 1 µm phase thickness). In addition, 0.5 µl samples of deoxygenated 
25-100% 1,2-propanediol treated with NO gas were injected in the GC-MS, now 
equipped with an Agilent DB-1701 column (0.25 mm i.d., 30 m length, 0.25 µm 
phase thickness), in a total He flow of 30 ml min-1, split fraction 1:5. In all analyses, 
the initial temperature was 40° C and was increased by 10° C min-1 until a 
temperature of 200°-250° C was reached. Mass spectrometry was either performed in 
electron impact mode, or in chemical ionisation mode using a chemical ionisation 
interface supplied with a methane flow. Detection of eluted compounds was made by 
an Agilent 5973 Mass Selective Detector. Data were collected and analysed with 
computer software and a library of mass spectra. 
3.2. RABBIT IN VIVO MODEL (PAPER I-IV) 
3.2.1. General procedure (Paper I-IV) 
Rabbits (New Zealand White, 2.0-3.5 kg) were anaesthetised with pentobarbital 
sodium (40-70 mg kg-1 body weight) intravenously through an ear vein. Mechanical 
ventilation (respiratory rate 40 min-1) with charcoal-filtered air was achieved by 
tracheostomy, insertion of a tracheal cannula and a rodent volume-controlled 
ventilator. The expiratory gas flow was altered between a lower positive end 
expiratory pressure (PEEP, 9 min, 1-2 cm H2O) and a higher PEEP (1 min, 4-6 cm 
H2O) in order to optimise ventilation and to prevent formation of atelectasis. 
Insufflation pressure, tidal volume, and CO2/O2 in inspiratory and expiratory gases 
were measured at side arms of the tracheal cannula or by a Datex Pedi-lite+ flow 
sensor and gas sampler immediately after the tracheal cannula. Nitric oxide in mixed 
exhaled gas (FENO) was continuously measured by a chemiluminescence-based 
system sampling at 100-140 ml min-1 through a Naphion sampling catheter at the end 
of a mixing chamber (size: 5 tidal volumes) connected to the ventilator exhaust. Tidal 
volume was adjusted to attain an end-tidal CO2 concentration of 4.5-5.5% at baseline. 
Body temperature of 38-39° C was maintained by use of a heating pad and a hot-
water heated bench. During the experiments the animals received a continuous 
intravenous infusion, via an ear vein, of glucose (24-26 g l-1), dextran 70 (27-28 g l-1) 
and sodium bicarbonate (6.2-6.6 g l-1) to compensate for fluid loss and to maintain an 
adequate blood acid-base status. Pentobarbital sodium was added to the infusate (2.1-
4.2 g l-1) to maintain anaesthesia. In paper I and II the animals were paralysed with 
addition of pancuronium bromide to the infusate (98 mg l-1). The infusion rate was 
administered at a rate of 5 or 10 ml kg-1 h-1 depending on the extent of surgery. 
Systemic arterial blood pressure and heart rate were measured and arterial blood 
samples were collected from a heparinised catheter in the left common carotid artery. 
Material for pulmonary embolisation and drug infusions were administered into a 
saline carrier flow via a catheter in the right jugular vein with the tip approximately at 
heart level.  
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3.2.2. Measurement of pulmonary hemodynamics and gas exchange 
parameters (Paper III, IV) 
The animals were prepared as above and a median sternotomy was performed. A 
heparinised catheter was inserted in the left jugular vein and advanced to the 
pulmonary artery for measurement of pulmonary arterial pressure and sampling of 
mixed venous blood for blood gas analysis. An ultrasonic flow probe was placed 
around the ascending aorta and this blood flow was considered as cardiac output. A 
catheter was introduced into the left atrium through a puncture wound in the left heart 
auricle for measurements of left atrial pressure. The open thorax was covered with 
plastic foil to minimise fluid loss. Synchronously collected samples of mixed exhaled 
gas, arterial blood and mixed venous blood were analysed and the values were used in 
the calculation of physiological dead-space ventilation and venous admixture (see 
paper IV for these and other calculations).  
3.2.3. Experimental pulmonary hypertension (Paper III) 
Acute pulmonary hypertension was induced by means of a continuous intravenous of 
the thromboxane A2-mimetic U46619 (150-300 ng kg-1 min-1) to reach a mean 
pulmonary arterial pressure of 30-35 mmHg. When a stable state of pulmonary 
hypertension was reached, the effects of intravenous infusions of NO donor solutions, 
on pulmonary and systemic hemodynamics and on blood gases, were evaluated.  
3.2.4. Experimental pulmonary embolism (Paper I, II, IV) 
Animals were prepared and monitored according to the general procedure. In paper I, 
pulmonary embolism was induced by a fast intravenous infusion (500 µl min-1) of air 
(100 µl kg-1) in order to induce pulmonary gas embolism. In paper II and IV, acute 
pulmonary embolism was induced by means of an intravenous infusion of 
homogenised autologous skeletal muscle tissue to mimic acute pulmonary embolism 
of solid material and it was prepared by modification of a previously described 
method (183). The right anterior tibial muscle was resected and placed in saline. 
Visible connective tissue and blood was removed, the muscle piece was dissolved in 
saline to a concentration of 0.1 g muscle ml-1 and homogenized. Heparin was added to 
the mixture (50 IE heparin ml-1), in order to prevent clotting of the solution. The 
homogenate was passed through a 0.5-1 mm mesh to prevent obstruction in the three-
way stopcock of the venous catheter. In paper I and II some groups of animals were 
pre-treated with the NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-
NAME; 30 mg kg-1), before pulmonary embolisation, in order to evaluate the function 
of endogenous NO in acute pulmonary embolism. This dose of L-NAME has 
previously been shown to abolish FENO and to increase the pulmonary vascular 
resistance by 75% in rabbits (5). In paper I, CO2 was added to inhaled gas of one 
group of animals 5 min after pulmonary embolisation in order to normalise airway 
CO2 concentration. In paper II, several different doses of MPE (7.5-60 mg 
homogenised muscle kg-1 body weight at 15 mg kg-1 min-1) was administered to 
different groups with intact and inhibited endogenous NO production. The animals 
were followed for at least 60 min after pulmonary embolisation and in paper II the 
survival of each group was evaluated. In paper I and II the effect of pulmonary 
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embolisation was evaluated on respiratory gases including exhaled NO, blood gases 
and systemic hemodynamics. 
In paper IV, deoxygenated NO-treated 1,2-propanediol (25% in saline, v/v, containing 
9 mM of the organic mononitrites of 1,2-propanediol in Figure 6, denoted PDNO), 
placebo (1,2-propanediol, 25% in saline, v/v, denoted PD) or of control solution 
(saline) were administered intravenously 20-60 min after acute pulmonary 
embolisation (30 mg muscle kg-1). The dose of pulmonary emboli was determined in 
pilot experiments and by the results in paper II, in order to induce moderate 
pulmonary embolisation that was large enough to be a considerable challenge but 
small enough so that all animals survived the observation period. The effects were 
evaluated on respiratory gases including exhaled NO, blood gases, methaemoglobin 
formation, systemic and pulmonary hemodynamics, right ventricle rate-pressure 
product, physiological dead space and venous admixture (see paper IV for 
calculations). 
3.2.5. Evaluation of the in vivo NO donating capacity and selectivity of 
NO donor solutions (Paper III) 
Initial experiments included infusions in rabbits of deoxygenated NO-treated saline 
and deoxygenated NO-treated lipid emulsion as means of administering NO gas 
intravenously. In further experiments, rabbits received the candidate NO donor 
solutions (prepared as above, Table 1) intravenously (3-300 µl kg-1 min-1) into a 
carrier flow of saline. Each rabbit received more than one of the NO donor solutions 
and were allowed ample intervention-free periods between infusions to reach stable 
baseline conditions and to exclude cross-tolerance. Arterial blood samples were 
intermittently analysed for blood gases and methaemoglobin. In some experiments the 
endogenous NO production was inhibited with L-NAME (30 mg kg-1). The capacity 
of NO donation in vivo was determined positive if both FENO increased and mean 
systemic arterial blood pressure (MAP) decreased. The relative effects of the 
individual NO donor solution on FENO (increase in ppb from baseline) and MAP 
(change in % of baseline) were considered as a measure (change in % of baseline 
divided with increase in ppb from baseline; MAP/FENO-index) of selectivity towards 
the pulmonary and systemic circulation respectively. 
3.2.6. Investigation of NO donating capabilities of the organic nitrites of 
1,2-propanediol, inorganic nitrite and NO gas (Paper IV) 
PDNO, 1,2-propanediol (25% in saline, v/v) solutions with and without addition of 
inorganic nitrite (20 mM) and deoxygenated NO-treated saline (Saline+NO) were 
given intravenously to rabbits in dose-response experiments. The added amount of 
inorganic nitrite in the 1,2-propanediol+nitrite (PD+nitrite) solution was chosen to 
approximate the total content of organic plus inorganic nitrites in the PDNO solution 
(Table 1). The effects of the infusions on FENO, MAP, heart rate, blood gases and 
methaemoglobin were evaluated. 
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3.2.7. Computation of physico-chemical descriptors of the NO donor 
molecules (Paper III) 
The calculator plugin modules of MarvinSketch were used to obtain molecular 
descriptors of the NO donor molecules. These descriptors included octanol/water 
partition coefficient (Log P), molecular size descriptors (molecular weight, molecular 
surface area, molar refractivity, maximal and minimal projection radii and projection 
area, polarizability), molecular shape descriptors (the ratios between maximal and 
minimal projection radii and projection area respectively) and polar and non-polar 
surface area. The relative polar surface area of each donor molecule was calculated by 
dividing polar surface area with molecular surface area. These descriptors were then 
used as independent variables in multiple linear regression models using the log (-
MAP/FENO-index) as the dependent variable. The best fits were determined by using 
the best subset function of the statistical software. 
3.3. STATISTICAL ANALYSIS (PAPER I-IV) 
Descriptive data are presented as mean ± standard error of the mean. Comparisons 
between groups were made by the student t-test or one way ANOVA and repeated 
comparisons within one group were made by a paired t-test or repeated measures 
ANOVA. Repeated comparisons between two groups were performed by two-way 
ANOVA on repeated measures. Survival was analysed with Fischer’s exact test and 
survival fraction was calculated according to the Kaplan–Meier method. Linear 
correlations were made by using Pearson Product Moment Correlation. Multiple 
linear regressions were made by using the best subsets function. Models including 
variables with non-significant variables (P>0.05) or with severe multicollinearity 
(Variance Inflation Factor>4) were excluded. P<0.05 was considered statistically 
significant. All statistical analyses were made by means of SigmaStat (v. 3.10.0) and 
SigmaPlot (v. 9.01, Systat Software Inc., San Jose, CA, USA).  
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4. RESULTS AND DISCUSSION 
4.1. EFFECTS OF PULMONARY EMBOLISATION (PAPER I, II, IV) 
Acute pulmonary embolisation with both air and solid emboli in these rabbits rapidly 
increased FENO (Figure 1). The increase in FENO peaked within 5-10 min after 
pulmonary embolisation and the peak increase represented approximately a doubling 
of FENO. After the peak increase, FENO slowly declined towards baseline values. In 
pulmonary gas embolism FENO was normalised within 30-50 min. This is in 
agreement with that pulmonary gas embolism resolves by itself within 30 min after air 
infusion (94). In experiments with solid emboli the increase in FENO was still 
significant 60 min after severe and moderate pulmonary embolisation. The time 
course of the rise in FENO (fast peak followed by a slow decline) resembles the time 
course of the release of mediators in acute pulmonary embolism, e.g. thromboxane A2 
and serotonin (188, 227). In parallel to the increase in FENO in both models of 
pulmonary embolisation, end-tidal CO2 decreased and MAP decreased while heart 
rate was unchanged. The arterial partial pressure of O2 and CO2 decreased 
respectively increased and arterial pH decreased, after pulmonary embolism. From the 
experiments with solid emboli, it is evident that these changes including the increase 
FENO are dependent on the dose of embolic material (Figure 1). Pulmonary 
embolisation increased pulmonary arterial pressure, pulmonary vascular resistance 
and right ventricle rate-pressure product (Figure 10). Physiological dead-space 
ventilation and venous admixture increased after pulmonary embolisation.  
 
 
Figure  1.  The  responses  of  exhaled  NO  (panel  A,  FENO)  and  end‐tidal  CO2  (panel  B, 
ETCO2) to acute pulmonary embolisation with an  intravenous  infusion of either air (100 
µl kg‐1 at 500 µl min‐1) or autologous homogenised skeletal muscle (MPE 15‐60 mg kg‐1 at 
15 mg kg‐1 min‐1). Data compiled from paper I and II. 
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Methodological considerations on experimental models of acute pulmonary embolism 
There are several ways of inducing experimental pulmonary embolism including 
intravenous infusion of autologous blood clots (188, 227), of gas (193), of 
microspheres (27) and of autologous muscle (70, 160, 183, 215-217). In the present 
thesis work we used gas and autologous homogenised muscle to induce pulmonary 
embolism to mimic pulmonary gas embolism and pulmonary thromboembolic disease 
in humans. Pilot experiments with intravenous infusions of coagulated and 
homogenised blood showed that haemoglobin release during embolisation interfered 
with exhaled nitric oxide measurements, i.e. free haemoglobin scavenged NO 
produced in the lung. In addition, intravenous infusions of coagulated blood indicated 
that this method was less reproducible and that the emboli slowly resolved by itself in 
the presence of small amounts of heparin (from the heparinised catheters). We did not 
use thrombin when coagulating the clot which probably would have produced more 
stable emboli (188, 227). Importantly, in these pilot experiments the initial response 
on the measured parameters (e.g. FENO, pulmonary vascular resistance and blood 
gases) to intravenous infusions of coagulated blood was completely similar to 
intravenous infusions of gas and homogenised muscle. As outlined in the introduction 
of the present thesis, all the changes of measured parameters, except the raised CO2 in 
arterial blood, are consequences of acute pulmonary embolisation also in humans, 
thus validating that the used models of acute pulmonary embolism are representative 
for the disease in humans. The increase in arterial partial pressure of CO2 is due to the 
decreased gas exchange area (i.e. increased physiological dead-space ventilation) and 
is a consequence of that the mechanical ventilation was not adjusted after pulmonary 
embolisation as it is in spontaneously breathing subjects by hyperventilation. Indeed, 
autologous muscle infusion is suggested to mimic the acute phase of pulmonary 
embolisation (183) and to produce immediate and consistent hemodynamic changes 
comparable with those occurring in humans with massive and diffuse PE (160). 
Another factor that may affect the response to pulmonary embolisation is the size of 
the emboli. It might be that small emboli induce a shunt and the larger emboli induce 
areas of increased ventilation-perfusion ratios (53, 54). Whether such a comparison is 
relevant for the present studies is not known. 
4.2. EFFECTS OF CO2 SUPPLEMENTATION ON EXHALED NO IN 
PULMONARY EMBOLISATION AND EFFECTS OF THROMBOXANE A2-
MIMETIC ON EXHALED NO (PAPER I, III) 
Normalisation of airway CO2 5 min after pulmonary gas embolisation rapidly 
attenuated the increase in FENO by approximately 50% (Figure 2). This finding 
suggests that a part of the increase in FENO in pulmonary embolism is due to reduced 
inhibition of CO2 on the pulmonary production of NO. Notably intravenous infusion 
of U46619, a thromboxane A2-mimetic, did not change FENO despite inducing a 
significant pulmonary hypertension, thus indicating that thromboxane-receptor 
agonism does not increase FENO (paper III). The finding that normalising CO2 after 
pulmonary embolisation attenuates the increase in FENO is concordant with that 
airway CO2 is a regulator of pulmonary NO production (4, 210). This effect and other 
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tentative mechanisms for the increase in FENO in pulmonary embolism will be 
discussed in section “General discussion”. 
 
 
 
Figure  2.  Anaesthetised  and  ventilated  rabbits.  Experimental  recordings  of 
fraction of NO  in mixed exhaled gas (FENO) and end‐tidal CO2 (ETCO2) following 
intravenous bolus  infusion of air  (100 μl kg‐1 at a rate of 500 μl min‐1). Panel A, 
control animal; Panel B, animal where CO2 was added to the inspired gas to yield 
ETCO2 of 110 ± 5 % of pre‐infusion levels. Figure 1 in paper I.   
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4.3. EFFECTS OF INHIBITION OF ENDOGENOUS NO PRODUCTION IN 
COMBINATION WITH ACUTE PULMONARY EMBOLISM (PAPER I, II) 
Endogenous enzymatic NO production was inhibited by L-NAME (30 mg kg-1, i.v.) 
30 min before pulmonary embolisation with either gas (100 μl kg-1 at a rate of 500 μl 
min-1) or solid emboli (7.5-30 mg kg-1). L-NAME treatment per se decreased FENO 
to below detection limit (<1 ppb) and increased MAP (by approximately 15-20 
mmHg). Heart rate decreased in some groups of animals and blood-gas values were 
not affected by L-NAME. It is previously known that inhibition of endogenous NO 
production in rabbits increases pulmonary vascular resistance and that acute inhibition 
of NO synthesis is well tolerated in rabbits (5, 177). Acute pulmonary embolisation 
with both air and solid emboli in the presence of L-NAME evoked severely 
augmented hemodynamic responses and blood-gas values indicating increased 
sensitivity towards pulmonary embolisation. All animals with intact NO production 
survived at least 60 min after intravenous gas infusion and solid emboli infusion 
(Figure 3). In contrary, all animals that were pre-treated with L-NAME died within 40 
min after the venous gas infusion. Similarly, the survival of animals pre-treated with 
L-NAME in combination with solid pulmonary embolisation was significantly 
decreased (Figure 3). These results clearly show that the endogenous NO production 
is protective in acute pulmonary embolism. Previously shown, NOS inhibition 
reduced the dose of collagen+adrenalin required to induce thromboembolic mortality 
in mice (69). NOS inhibition has been shown to increase bubble formation after 
decompression and reduce survival in rats (239). Our results has also been confirmed 
by others in a canine model of acute pulmonary embolism with autologous blood clots 
(60). Attempts have also been made to define the role of NO derived from the 
inducible NOS, however these results are conflicting (59, 60), perhaps due to non-
specific effects of the inhibitors used (164).  
 
 
Figure  3.  Anaesthetised  and 
ventilated  rabbits.  The  lines 
represent  the  survival  proportion 
during  the  first  60 min  after muscle 
tissue pulmonary embolisation  (MPE 
administered at  time 0)  for  the non‐
pretreated  groups  [long‐dash  line; 
MPE of 60 (n=6), 15 (n=5), or 7.5 mg 
kg‐1  (n=5)]  and  the  L‐NAME  (30  mg 
kg‐1  i.v.)  pretreated  groups  [MPE  of 
30  (n=4,  single‐dot  line),  15  (n=6, 
short‐dash  line), or 7.5 mg kg‐1  (n=6, 
dash‐dot line)]. Figure 4 in paper II. 
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4.4. FORMATION OF NEW NO DONORS BY USING NITRIC OXIDE GAS 
The first part of this thesis work clearly demonstrated a protective role of the 
endogenous NO production in acute pulmonary embolism and therefore it was 
hypothesised that exogenous NO would be beneficial in this condition. It was 
believed that an intravenous lung-selective NO donor would be preferable since 
inhaled NO in acute pulmonary embolism only caused moderate decreases of the 
pulmonary hypertension (248) and that nitroglycerin and sodium nitroprusside caused 
detrimental systemic hypotension (143). Such an NO donor must have increased 
selectivity for the pulmonary circulation in order to avoid systemic hypotension and 
lack tolerance development. It was felt that the presently available NO donors did not 
fulfil these criteria and therefore we explored new ways of delivering NO 
intravenously. 
4.4.1. Exploration of NO donating capacity in vivo (Paper III) 
Due to the lipophilicity of the NO molecule, it was first hypothesised that NO gas 
dissolved in a lipid emulsion was a way to deliver NO gas intravenously to the 
pulmonary circulation. Deoxygenated saline equilibrated with NO gas administered 
intravenously to a rabbit with inhibited NO production (L-NAME 30 mg kg-1) 
resulted in a small increase in FENO and a very high methaemoglobin concentration 
(Figure 4). In contrary, an infusion of deoxygenated NO-treated lipid emulsion at the 
same infusion rate in the same animal yielded a large increase in FENO whereas 
methaemoglobin was essentially not changed (Figure 4).  
 
 
 
 
 
Figure  4.  Anaesthetised  and 
ventilated  rabbit.  Exhaled  NO 
(FENO,  panel  A)  and 
methaemoglobinemia  (met  Hb, 
panel B)  during  infusion  (0.5 ml 
kg‐1 min‐1) of deoxygenated NO‐
treated saline and deoxygenated 
NO‐treated  lipid  emulsion,  as 
indicated  by  horizontal  bars. 
Endogenous NO production was 
inhibited  (L‐NAME  30  mg  kg‐1, 
indicated  by  a  horizontal  bar). 
Figure 1 from paper III. 
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Table 1. Overview of the formation and the  identification of organic nitrites when reacting 
deoxygenated aqueous solutions of parent compounds with pure NO gas. 
Parent compounds NO donation 
in vivo 
UV absorbance 
in HPLC 
NO release 
in LC-NO 
Identified 
by GC-MS 
 
1-Propanol + +* +# +  
1,2-Propanediol + + + +  
Glycerol + + +   
Glucose + + +   
Ethanol  +* +#   
Isobutanol + +*    
Butanol  +*    
Sucrose + +    
2-Propanol +     
1,3-Propanediol +     
2-Deoxyribose +     
1-O-Methyl-2-deoxyribose +     
Ribose +     
6-Deoxygalactose +     
Galactose +     
Fructose +     
Sorbitol +     
Mannitol +     
Lactobionic acid +     
Polyethylene glycol +     
Inulin +     
Dextran +     
Fucoidan +     
2-Amino-1,3-propanediol –     
3-Amino-1,2-propanediol –     
Lactic acid –     
Alanine –     
Glycine –     
Glucosamine –     
NO donation  in  vivo was determined positive  if both  exhaled NO  increased  and  systemic 
arterial  blood  pressure  decreased  (+).  –  denotes  no  NO  donation  capacity  in  vivo.  UV 
absorbance in HPLC was denoted (+) if treatment with NO gas of parent compounds resulted 
in  new  chromatographic  peaks  exhibiting  characteristic  absorbance  around  225  nm  and 
vibrational  absorbance  in  the  range  330‐370  nm  (225).  *denotes  that  the  new 
chromatographic peaks in HPLC had the same retention time and UV characteristics in HPLC 
as  the  corresponding  authentic  and  commercially  available  organic  nitrite. NO  release  in 
HPLC coupled to on‐line nitrite reduction (LC‐NO) was indicated (+) if new chromatographic 
peaks also were  confirmed  to  release NO  in  the nitrite  reduction  system.  #  indicates  that 
authentic organic nitrite  of  the parent  compound  also  released NO  at  identical  retention 
time  in  the  LC‐NO.  Some  of  the  formed  compounds  (+)  were  identified  with  gas 
chromatography‐mass spectrometry (GC‐MS). Non‐filled spaces in the table indicate that the 
corresponding analysis was not performed  for  that  compound  in  that  system. Absence of 
markers # and * means  that commercial reference compounds were not available. Table 1 
from paper III. 
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An important observation was that the lipid emulsion turned yellow indicating 
oxidation. In order to find a more pure NO donating solution and since the lipid 
emulsion contained glycerol, deoxygenated NO-treated glycerol (glycerol-NO; 25% 
in saline, v/v) was infused intravenously (100 µl kg-1 min-1) in another rabbit (pre-
treated with L-NAME 30 mg kg-1) which resulted in increased FENO and decreased 
MAP. Exhaled NO and MAP remained unchanged during intravenous infusions of 
deoxygenated NO-treated saline and glycerol at the corresponding infusion rates. 
These experiments suggested that an NO donor solution was created when 
deoxygenated solutions of lipid emulsion or glycerol were treated with NO gas.  
Thereafter more than 20 different deoxygenated NO-treated solutions of alcohols and 
carbohydrates (Table 1) were administered intravenously (100 µl kg-1 min-1) to rabbits 
in order to test their NO donating capabilities. The capacity of NO donation in vivo 
was determined positive if both FENO increased and MAP decreased. Deoxygenated 
NO-treated alcohols, polymers of alcohol, monosaccharides, monosaccharide 
alcohols, certain modified monosaccharides, disaccharides and carbohydrate polymers 
presented NO donating capacities (Table 1). Some of the NO donor solutions induced 
methaemoglobinaemia, e.g. propanol-NO (deoxygenated NO-treated propanol, 25% 
in saline). A common feature for the compounds exhibiting NO donating capacity was 
that they contained at least one hydroxyl group. Some compounds did not donate NO 
in vivo despite deoxygenation and NO gas treatment (Table 1), indicating that amine 
or carboxyl groups close to the hydroxyl-group in the substrate molecule prevented 
the formation of the NO donor compounds.  
4.4.2. Identification of reaction products with liquid chromatography 
coupled to on-line nitrite reduction (Paper III, IV) 
HPLC coupled to on-line nitrite reduction (LC-NO) was developed in order to further 
characterise and identify the NO donating compounds. In the chromatogram and in 
the synchronised NO/nitrite recording several peaks were identified. First, a peak 
which was regarded as emanating from the NO gas and inorganic nitrite appeared in 
the front (denoted peak I) of all the analysed NO solutions including deoxygenated 
NO-treated saline and water solutions of inorganic nitrite (Exemplified by analysis of 
PDNO in Figure 5). Furthermore in all the deoxygenated NO-treated solutions 
investigated with HPLC or LC-NO (Table 1) there also appeared UV absorbing peaks 
with UV absorbance maxima near 225 nm and with the, for organic nitrites 
characteristic, vibrational spectral peaks in the range 330-370 nm (225). All these 
novel chromatographic peaks were capable to generate NO in the nitrite reduction 
system (Table 1). Neither in the HPLC nor in LC-NO were these novel peaks seen 
when deoxygenated but non-NO treated organic starting materials were analysed. The 
number of eluted organic nitrite-like peaks correlated with the number of nitrosylation 
sites in the form of hydroxyls in the parent compounds: deoxygenated NO-treated 
propanol (propanol-NO) yielded one peak, deoxygenated NO-treated 1,2-propanediol 
(PDNO) exhibited two peaks (II and III in Figure 5) and deoxygenated NO-treated 
glycerol (glycerol-NO) gave two peaks and deoxygenated NO-treated glucose 
(glucose-NO) gave 4 organic nitrite-like peaks. These experiments suggested that the 
reaction products between NO gas and the organic starting material were organic 
mononitrites.  
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In these experiments the concentration of inorganic nitrite and organic nitrites in the 
NO donor solutions were determined, by comparison with aliquots of inorganic 
nitrite, to 1-5 mM in these experiments. Since the concentration of the organic starting 
material was 3.3 M the relation between reacted parent molecules to un-reacted parent 
molecules would be approximately 1:1000, if each reacted parent molecule bound one 
NO. Therefore the detection of the organic nitrites by nuclear magnetic resonance 
against this background was considered nearly futile. Attempts at identification with 
LC-MS yielded no conclusive data (unpublished results).  
Methodological considerations on HPLC coupled to on-line nitrite reduction 
The present thesis introduced a method for analysing inorganic and organic nitrites in 
HPLC coupled to a nitrite reduction system. There are several methods for analysing 
nitrites (106). NO release from guinea-pig colon (103) and from rabbit corpus 
cavernosum (89) has previously been studied in our laboratory by using the nitrite 
reduction system alone. A partly similar system (isocratic HPLC elution coupled to 
nitrite reduction) to analyze inorganic nitrite in food, saliva and urine has been 
described (195). We used both isocratic and gradient elution in the HPLC and the 
method offered both high sensitivity (at least 10 pmoles, by the chemiluminescence) 
and specificity (different retention times by HPLC). The methods were used to 
identify organic nitrites that could not be identified with GC-MS or LC-MS. Caution 
must be taken in that some other compounds might give a signal in the ozone reaction 
(e.g. ethers) and that the nitrite reduction system can reduce both inorganic nitrite and 
organic nitrites, as well as N-nitrosylated and S-nitrosylated compounds (229). 
 
Figure 5. HPLC  (panel A)  coupled  to 
reflux NO/nitrites  analysis  (panel  B) 
for  identification  of  inorganic  and 
organic  nitrites.  Chromatogram 
obtained  at  227  nm  (panel  A)  and 
nitrite content  (panel B) of 2.5 µl of 
deoxygenated  NO‐treated  1,2‐
propanediol  solution  (25%  in  saline, 
v/v),  injected  at  time  0.  Isocratic 
elution  (10 mM ammonium  formate 
in water) using a C18 column. Peak  I 
corresponded  to  NO/inorganic 
nitrite. Peak  II and  III had major UV 
absorbance maxima at 225 and 226 
nm  respectively  and  also  exhibited 
vibrational spectra in the region 330‐
370  nm,  characteristic  for  organic 
nitrites (225). Figure 4 in paper III. 
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4.4.3. Identification of reaction products with gas chromatography-mass 
spectrometry (Paper III) 
Using GC-MS, propyl nitrite was identified in the C18 HPLC fractions corresponding 
to the novel chromatographic peak from propanol-NO. Gas chromatography-mass 
spectrometry of commercial propyl nitrite confirmed the identification, thus it was 
concluded that the reaction product in propanol-NO was propyl nitrite. Furthermore 
two novel compounds in the PDNO sample were identified by GC-MS. The mass 
spectra of these peaks were suggested to arise from the organic mononitrite of 1,2-
propandiol when the hydroxyl at position 1 is nitrosylated (2-hydroxy propyl nitrite, 
compound (1) in Figure 6) and from the mononitrite of 1,2-propandiol when the 
hydroxyl at position 2 is nitrosylated (2-hydroxy-1-methylethyl nitrite, compound (2) 
in Figure 6). Mass spectrometry using chemical ionization showed the expected 
molecular ions in the mass spectra for both compound 1 and 2, thus verifying that the 
two reaction products in PDNO, also seen in LC-NO (Figure 6), were the two organic 
mononitrites of 1,2-propanediol. To our knowledge these compounds have never been 
identified before and they received CAS numbers based on our identification. 
Determination of the reaction products of glycerol-NO by the same method failed due 
to chromatographic interference from the large amounts of unreacted glycerol. 
 
Figure  6.  The  two  organic  nitrites  in  the  PDNO 
solution.  (1)  is  2‐hydroxy  propyl  nitrite  (IUPAC 
name: 1‐(nitrosooxy)propan‐2‐ol; CAS no. 950478‐
72‐5). (2)  is 2‐hydroxy‐1‐methylethyl nitrite (IUPAC 
name: 2‐(nitrosooxy)propan‐1‐ol; CAS no. 950478‐
73‐6). Figure 1 in paper IV. 
4.4.4. Comparisons with commercially available organic nitrites and the 
reaction products between NO gas and alcohol starting material (Paper 
III) 
Further experiments were performed to verify the formation of organic nitrites. When 
analysing commercially available propyl nitrite and propyl nitrate there was a perfect 
match between the elution time and UV absorbance spectra between peak II in 
propanol-NO and authentic propyl nitrite, whereas the retention time and UV 
absorbance spectrum of propyl nitrate were completely different. The content of 
propyl nitrate, if any, in the propanol-NO must be less than 2.5% of the content of 
propyl nitrite (calculated on detection limits). Further comparisons with other 
commercial organic nitrites in HPLC and LC-NO were completely compatible with 
formation of the corresponding organic nitrites in the NO gas treated hydroxyl 
precursor solutions (Table 1). These experiments provided further evidence that the 
reaction products between NO gas and organic starting material yielded organic 
nitrites. Also interesting, in the experiments with authentic organic nitrites it was 
found that the stability of the authentic organic nitrites was poor in water and was 
markedly increased by dissolving them in deoxygenated water or more preferable in 
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deoxygenated NO gas-saturated solution. These experiments suggested that one 
advantage of our production method of organic nitrites was that deoxygenation and 
the presence of NO gas increased the stability of the organic nitrites in the solution.  
4.4.5. Summary of evidence that organic nitrites are formed in the 
reaction between NO gas and organic starting material containing at 
least one hydroxyl group (Paper III)  
The reaction products between propanol and NO gas and between 1,2-propanediol 
and NO gas were identified to be propyl nitrite, a previously known organic nitrite 
and the two possible organic mononitrites of 1,2-propanediol respectively (Figure 6). 
It is most likely that the other NO donor solutions also contain the organic 
mononitrites of the organic starting material, because: (1) They were produced with 
the same method that produced organic nitrites unequivocally identified by GC-MS; 
(2) They showed similar NO donor capabilities in vivo; (3) The number of reaction 
products was associated with the number of hydroxyl groups in the carrier molecule. 
(4) UV absorbance maxima were around 219-234 nm and they exhibited 
characteristic vibrational spectra (225); (5) They released NO in the nitrite reduction 
system. (6) The starting materials for the reactions were known. 
The present thesis work did not aim to elucidate the mechanism by which the organic 
nitrites were formed in the reaction with NO gas. It is difficult to exclude trace 
amounts of oxygen in the reaction chamber. Therefore the reaction may involve a 
direct action of NO on the hydroxyl groups of the carrier molecules or it may involve 
a nitrosating agent such as N2O3 (formed by the reaction of NO gas and trace amounts 
of oxygen) or it may be another, for us unknown, mechanism.  
4.4.6. Determination of the content of NO gas, inorganic nitrite and 
organic nitrites in the PDNO solution and deoxygenated NO-treated 
saline (Paper IV) 
Since the NO donor solutions contained NO gas and inorganic nitrite, which may also 
be bioactive (45), it was considered important to determine the content of NO-gas, 
inorganic and organic nitrite in the PDNO solution and in deoxygenated NO-treated 
saline (Saline+NO) and to perform dose-response experiments in vivo with 
appropriately selected solutions. In addition it was found that the content of organic 
nitrites could be increased by prolonging the time for purging the solution with NO 
gas and by using a small glass chamber. Therefore the contents of inorganic and 
organic nitrite are larger compared to that indicated in Figure 5, which is favourable 
in order to limit the infusion of un-reacted starting material and to make infusions in 
larger animals and humans more feasible. The NO gas content of the PDNO solution 
(0.6 mM) was determined to one third of the NO gas content in the Saline+NO 
solution (Table 2). The total contents of NO/nitrites in the PDNO solution were 
comparable to that in the Saline+NO solution (Table 2). The concentration of organic 
mononitrites of the PDNO solution was 15 times higher than that of NO gas in the 
same solution (Table 2).  
Therefore in the dose-response experiments with PDNO (se below), a 1,2-propanediol 
solution (25% in saline, v/v) with addition of 20 mM of inorganic nitrite (PD+nitrite) 
and the deoxygenated NO-treated saline solution were infused as control solutions at 
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the same infusion rates as PDNO. Thereby the Saline+NO solution served as a control 
for both inorganic nitrite and NO gas (actually three times more NO gas). The 
PD+nitrite solution served as a control for the total inorganic nitrite content in 
combination with 1,2-propanediol. 
 
Table  2.  Determination  of  concentrations  of  nitrogen  oxides  in  the  PDNO  solution 
(deoxygenated NO‐treated 1,2‐propanediol 25% v/v in isotonic saline) and its corresponding 
NO‐saturated saline control, used in the dose‐response experiments. 
 PDNO Saline+NO 
Direct injections in reflux system    
a)with nitrite reducing agent   
Total NO gas + nitrites (mM) 20.0±0.2 22.0±0.4 
b)without nitrite reducing agent   
NO gas (mM) 0.6±0.1 1.7±0.1 
   
LC-NO (HPLC followed by nitrite 
reduction) 
  
Inorganic nitrite=Peak I (mM) 7.8±0.1 20.2±0.5 
Organic nitrites=Peak II+III (mM) 9.1±0.1 0 
  
Deduced total content of nitrogen oxides   
Peak I+II+III + NO gas (mM) 17.5±0.1 21.9±0.6 
Samples  were  analysed  by  means  of  direct  injections  into  the  reflux  system  for  nitrite 
reduction coupled to chemiluminescence detection (total NO gas/nitrite determination) and 
without nitrite  reducing  agent  (NO  gas determination)  and by means of  LC‐NO,  i.e. HPLC 
(isocratic  C18  column,  elution  with  7%  of  acetonitrile  in  10  mM  ammonium  formiate) 
followed by on‐line nitrite reduction  in  the reflux system  (peak  I,  II,  III  in Figure 5). N=3‐6. 
Peak I in the HPLC eluted at the retention time of inorganic nitrite and was deemed free of 
NO gas as judged from experiments in the absence of reducing agent (data not shown). Peak 
II and III had previously been shown to be the organic nitrites in Figure 6. Table 1 in paper IV. 
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4.4.7. Further exploration of in vivo effects of new organic nitrites and in 
comparison with NO gas and inorganic nitrite (Paper III, IV) 
PDNO increased FENO and decreased MAP dose-dependently (Figure 7), whereas 
Saline+NO and PD+nitrite, at the highest doses used, only had a small effect on MAP 
without affecting FENO (Figure 7). Methaemoglobin increased at the highest doses of 
all three solutions but remained below 2.0% in all animals (Figure 7). These 
experiments clearly show that PDNO is a powerful vasodilator, even in the systemic 
circulation, at the highest doses. Compared with inorganic nitrite at similar doses, 
PDNO is more than 15 times more potent on MAP. These data also suggest that it is 
the inorganic nitrite and not the NO gas of the Saline+NO solution which is bioactive. 
Importantly, hemodynamic effects of inorganic nitrite, in contrast to PDNO, are 
associated with methaemoglobin. This is not surprising since the present theory for 
activation of inorganic nitrite to bioactive NO by deoxyhaemoglobin involves 
formation of methaemoglobin (45). Also in humans, systemic hemodynamic effects of 
inorganic nitrite are associated with severe methaemoglobin formation (45, 97). In 
dogs, inorganic nitrite (450 nmol kg-1 min-1 for 15 min followed by 280 nmol kg-1 
min-1 for 105 min) decreased systemic blood pressure (by approximately 30 mmHg) 
and also decreased cardiac output, but unfortunately methaemoglobin was not 
monitored (57). These findings indicate that dogs and humans are more sensitive to 
inorganic nitrite than rabbits. It may also be that other species compared to rabbits are 
more sensitive to PDNO. Experiments with piglets and sheep indicate that those 
species are at least 4 times more sensitive to PDNO and that bioactive doses of PDNO 
are 30-60 nmol kg-1 min-1 in sheep and that corresponding control infusions of 
inorganic nitrite (60-120 nmol kg-1 min-1) are inactive (unpublished data).  
Furthermore, during infusions of the organic nitrite solutions both FENO and MAP 
quickly reached a stable plateau (exemplified by Glycerol-NO in Figure 8), indicating 
absence of acute tachyphylaxis. This is in contrast to nitroglycerin where a peak and 
plateau pattern has been observed and was taken as an indication of acute 
tachyphylaxis (13). The lack of acute tolerance in other organic nitrites has previously 
been shown both in vivo and in vitro (23). This important difference and perhaps other 
differences between organic nitrites and organic nitrates could encourage the use of 
organic nitrites instead of organic nitrates in clinical settings. 
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Figure  7.  Dose‐response  studies  of  nitrites  in  anaesthetised  and  ventilated  rabbits. 
Exhaled NO (FENO, panel A), change in systemic arterial blood pressure (MAP, panel B), 
change in heart rate (HR, panel C) and methaemoglobin (panel D) in ventilated rabbits 
subjected to  infusion of PDNO (organic nitrite), NO gas treated saline (Saline+NO) and 
inorganic  nitrite  (20 mM)  in  1,2‐propanediol  (25%  in  saline,  v/v)  at  increasing  dose 
rates. The lower and upper x‐axis in each panel show the dose of organic nitrite (for the 
PDNO)  and  the  total  dose  of  nitrites  (organic  nitrites  +  inorganic  nitrite)  of  all  the 
infusions, respectively. * denotes a significant difference compared to baseline within 
that group.  § denotes a significant difference between  the PDNO group compared  to 
both PD+nitrite and Saline+NO groups for that particular dose. N=4‐5 for each infusion. 
Figure 3 in paper IV. 
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Figure  8.  Anaesthetised  and  ventilated 
rabbits (n=5). Exhaled NO (FENO, panel A), 
mean arterial blood pressure (MAP, panel 
B) and heart  rate  (HR, panel C) during an 
intravenous  infusion  (30 ul  kg‐1 min‐1,  for 
10  min)  of  glycerol‐NO  (25%  glycerol  in 
saline,  v/v,  treated  with  NO  gas  and 
identified  by  LC‐NO  to  contain  glyceryl 
nitrites). Note  the plateau pattern of  the 
response,  indication  no  acute  tolerance 
development. Figure 3 in paper III. 
 
 
4.4.8. Determination of molecular physico-chemical properties of the 
organic nitrites that are important for selectivity for the pulmonary and 
systemic circulation respectively (Paper III) 
In the present work it was early noted that some organic nitrite solutions had large 
effects on FENO and minor effects on MAP. On the other hand other organic nitrites 
had large effects on MAP and small effects on FENO. A previously published 
MAP/FENO-index was used (13) that described these differential effects on MAP 
versus FENO, exerted by the different organic nitrites and taken as a marker for 
selectivity towards the systemic versus pulmonary circulation (refer to paper III for 
calculations). The interpretation was that a MAP/FENO-index away from zero 
indicated increased relative selectivity towards the systemic circulation and a 
MAP/FENO-index closer to zero denoted a relative selectivity towards the pulmonary 
circulation. It was hypothesised that the selectivity of the individual organic nitrite 
depended on properties of that molecule. It was found by using multiple regression 
that the relative surface polarity of the organic nitrite molecule was the best predictor 
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of the selectivity, i.e. the more relative surface polarity of the NO donor molecule, the 
more effects on MAP compared to FENO and vice versa (Figure 9). The most non-
polar organic nitrites induced methaemoglobin. Thereafter, PDNO and glycerol-NO 
were chosen as candidates to proceed with in further experimentation since they 
exhibited increased selectivity towards the pulmonary circulation, negligible 
methaemoglobin formation and low toxicity. Note that the relative selectivity may be 
overridden by a high dose of e.g. PDNO and glycerol-NO (Figure 7 and 8). Glucose-
NO was chosen as a candidate for comparison with increased selectivity towards the 
systemic circulation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure  9.  Anaesthetised  and  ventilated  rabbits  subjected  to  intravenous  infusions  of 
different organic nitrite NO donor  solutions. The MAP/FENO  indices were  calculated  from 
experiments with  intravenous  infusions  of NO  donor  solutions  by  dividing  the  change  in 
mean  systemic  arterial blood pressure  (MAP, % of baseline) with  increase  in  exhaled NO 
(FENO,  delta  ppb  compared  with  baseline).  Each  point  represents  one  NO  donor 
(deoxygenated and NO‐treated 1‐Propanol – Lactobionic acid  in Table 1). Shown  is also the 
best  linear  regression  found by exploring  the dependent  variable  Log  (‐MAP/FENO  index) 
against the independent variable relative polarity (polar surface area divided with molecular 
surface area  in %, PSA/MSA) for the different NO donors showing that relative polarity  is a 
strong predictor for MAP versus FENO effects. Figure 5 in paper III. 
 
4.4.9. Effects of certain organic nitrites in pharmacologically induced 
pulmonary hypertension (Paper III) 
The three candidates (PDNO, glycerol-NO and glucose-NO) were tested in a model of 
pharmacologically induced pulmonary hypertension (U46619, 150-300 ng kg-1 min-1) 
in a few rabbits. PDNO and glycerol-NO given intravenously effectively reversed the 
induced pulmonary hypertension with minor effects on MAP, unchanged blood gases 
and no methaemoglobin formation. Interestingly, glucose-NO also partially lowered 
the pulmonary hypertension but this effect was paralleled with severe systemic 
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hypotension. Thereby these experiments suggested, although not completely proved, 
that the differential effects on FENO and MAP of organic nitrites intravenously may 
be used as an indication of selectivity towards the pulmonary versus the systemic 
circulation. The MAP/FENO-index suggested that PDNO was slightly more selective 
for the pulmonary circulation compared with glycerol-NO and therefore PDNO was 
further investigated in acute pulmonary embolism. 
4.5. EFFECTS OF PDNO IN ACUTE EXPERIMENTAL PULMONARY 
EMBOLISM (PAPER IV) 
In two groups of rabbits where the pulmonary circulation and gas exchange 
parameters were monitored acute pulmonary embolisation (30 mg kg-1 homogenised 
muscle) resulted in the expected changes of the measured parameters (see above), 
including pulmonary hypertension (Figure 10), increased right ventricle rate-pressure 
product (Figure 10), increased physiological dead-space ventilation, and increased 
venous admixture. Treatment with either PDNO (200 nmol kg-1 min-1) or 1,2-
propanediol (PD; 25% in saline, v/v, at the same infusion rate) was performed 20-60 
min after pulmonary embolisation. PDNO increased FENO, decreased and normalised 
pulmonary vascular resistance and right ventricle rate-pressure product (Figure 10) 
whereas PD did not have these effects. PDNO decreased pulmonary arterial pressure, 
compared to values before start of treatment. The effects of PDNO were reversed 
when stopping the treatment (Figure 10). Systemic arterial blood pressure was similar 
in both groups. PDNO and PD did not change other measured parameters. 
Methaemoglobin was very modestly increased (by approximately 0.3%) at the end of 
PDNO treatment, compared to PD and baseline, and importantly all animals had 
methaemoglobin <1% during the study period.  
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Figure  10.  Anaesthetised  and  ventilated  rabbits.  The  response  of  pulmonary  vascular 
resistance  (PVR, panel A)  and  right  ventricle  rate pressure products  (RV RPP, panel B)  to 
pulmonary embolism  (PE)  induced at  time 0 min and  to  treatment started at 20 min. The 
two groups received placebo (1,2‐propanediol, PD) or 200 nmol kg‐1 min‐1 of 1,2‐propanediol 
mononitrites  (PDNO). * and  # denote a  significant difference  compared  to baseline  in  the 
placebo  group  and  in  the  PDNO  group,  respectively.  §  denotes  a  significant  difference 
between  the  two  groups  at  the  actual  time point. n=6  in  each  group. Part of  Figure 5  in 
paper IV. 
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5. GENERAL DISCUSSION 
One major finding in the present thesis is that exhaled NO increases during acute 
experimental pulmonary embolism. Another major finding is that endogenous NO is 
protective in acute experimental pulmonary embolism. A third major finding is that 
treatment with NO donating organic nitrites intravenously in acute pulmonary 
embolism is beneficial. These findings provide further knowledge on the function of 
NO in the lung and in particular in acute pulmonary embolism and certain aspects of 
these findings will be discussed below. In addition exhaled NO emerges as a method 
that should be tested in humans suffering from acute pulmonary embolism. 
Furthermore new organic nitrites were discovered and models describing their 
selectivity towards the pulmonary versus systemic circulation were developed. The 
mechanisms behind this selectivity will be discussed below as well as potential future 
use of these or other new organic nitrites in diseases with compromised pulmonary 
circulation. 
5.1. MECHANISMS BEHIND THE INCREASE IN EXHALED NO IN ACUTE 
PULMONARY EMBOLISM 
Several mechanisms that involve increased production and/or decreased elimination 
of pulmonary NO might contribute to the increase in exhaled NO following PE: 
5.1.1. Regulation of pulmonary NO production by airway/alveolar CO2 
and O2 
Acute pulmonary embolism leads to un-perfused or partly perfused parts in the lung. 
In these lung parts the alveolar content of CO2 is low (detected as decreased end-tidal 
CO2, paper I, II, IV) and the alveolar content of O2 is increased (detected as increased 
end-tidal O2, data not shown). As outlined in the introduction these two changes and 
especially the decrease in CO2 concentration will increase the pulmonary NO 
production and thus increase exhaled NO (4, 210, 243). Indeed, the present work 
shows that approximately 50% of the increase in exhaled NO after acute pulmonary 
embolism could be explained by the decreased alveolar CO2.  
5.1.2. Release of NO synthase stimulating substances 
Acute pulmonary embolisation is known to lead to the release of bioactive substances 
as outlined in the introduction (200, 209), which potentially can stimulate NO 
production and thus increase exhaled NO (209).  
Endothelin 
Endothelin-1 infusion has been shown to increase exhaled NO (134) and an non-
selective endothelin receptor antagonist decreased exhaled NO (95), thus indicating 
that endothelin-1 released during acute pulmonary embolism has the potential to 
increase exhaled NO. It has been proposed that the increase in exhaled NO due to 
endothelin-1 is mediated by activation of the endothelin-A-receptor (75).  
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Serotonin 
Treatment for 30 days of guinea-pigs with a serotonin re-uptake inhibitor increased 
exhaled NO, but lung inflammation occurred making interpretation difficult (32). It 
has been suggested that the pulmonary vasoconstrictive response to serotonin is partly 
attenuated by pulmonary endothelial NO release (144), but whether this tentative 
release can be seen as change in exhaled NO is uncertain. 
Thromboxane A2 
It is not likely that release of thromboxane A2 increases exhaled NO since intravenous 
infusion of thromboxane A2-mimetic U46619 in the present work and previous 
studies does not change exhaled NO (46, 85).  
5.1.3. Reduced scavenging of NO by haemoglobin 
Reduced binding of pulmonary NO to haemoglobin in the erythrocytes, owing to 
reduced blood flow and diminished blood volume in the lung capillaries, may increase 
exhaled NO (26). In support of this, completely stopping the pulmonary blood flow 
has been shown to increase exhaled NO (88). Furthermore it has been shown that 
occlusion of pulmonary arteries by wedging a pulmonary arterial catheter rapidly 
increases exhaled NO from the lung regions with occluded vessels (71). The increase 
in exhaled NO correlated with the decrease in blood flow but not with the increase in 
pulmonary arterial pressure (71).  
5.1.4. Regulation of inducible NO synthase 
Up-regulating the iNOS-gene, as in asthma, might be of importance in a later phase of 
pulmonary embolism. However, iNOS is not likely to be important in the acute phase 
owing to the time lag in induction of the enzyme (56).  
5.1.5. Effects of changes in blood gases 
Despite profound changes in blood gases during pulmonary embolism, the lowered 
arterial partial pressure of O2 (11, 100), the increased arterial partial pressure of CO2 
(243) and the decreased arterial pH (4) are not within the ranges needed to alter 
exhaled NO. From experiments with isolated buffer-perfused lungs, it has been 
convincingly shown that it is the airway/alveolar, and not the intravascular, 
concentration of CO2 and O2 that regulates exhaled NO (100, 243). 
5.1.6. The role of NO in matching ventilation and perfusion in the lung 
It is an intriguing idea that the increase in exhaled NO after pulmonary embolisation 
may be a sign of mechanisms in the lung geared towards increasing perfusion to well-
ventilated parts that are completely or partly obstructed by emboli or constricted due 
to the release of mediators. Well-ventilated and inadequately perfused lung parts are 
stretched and are characterised by low CO2 and high O2 concentrations and attenuated 
scavenging of NO by haemoglobin which all increase pulmonary NO production, as 
outlined above and in the introduction. Thus it has been suggested that the increased 
local NO concentration, in well-ventilated lung parts, may dilate the associated 
pulmonary vessel and thereby matches local ventilation and perfusion (6). Future 
studies are needed to further confirm this idea and these studies should preferably be 
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done in humans or in animals where the function and regulation of pulmonary NO is 
similar to humans.  
5.2. POTENTIAL USE OF EXHALED NO IN ACUTE PULMONARY 
EMBOLISM 
The present thesis work (paper I, II, IV) indicates that measurement of exhaled NO 
has a potential of being a marker for pulmonary embolisation of different genesis 
especially in the very acute phase. Of course this issue needs to be carefully evaluated 
in clinical studies involving humans suffering from acute pulmonary embolisation, 
but if it works it would be useful. Problems that need to be overcome include the 
interindividual variation of levels of NO in exhaled breath, establishing cut-off values 
and how to differentiate between other pulmonary diseases, in particular those 
associated with pulmonary inflammation, e.g. asthma (21). Another inherent problem 
is that the increase in exhaled NO one hour after acute pulmonary embolisation was 
small. On the other hand, it might not necessarily be so in humans.  
A situation where exhaled NO may be used, especially since the present study (paper 
II) shows that the increase in exhaled NO is dependent on emboli dose, i.e. severity, is 
when determining on the need for more intense treatment (e.g. thrombolysis), instead 
of only anticoagulation. It is known that although hemodynamically stable 
approximately 50% of the patients suffering from acute pulmonary embolism will 
show signs of right ventricular dysfunction, which is a negative prognostic predictor 
(82, 124). Therefore a subgroup of these patients is believed to benefit from more 
intense treatment (e.g. thrombolysis) but how to identify these patients remains an 
open question (125). Most of the nowadays used markers for risk stratification include 
measures of right ventricular dysfunction (echocardiographical signs or biochemical 
markers) (124) and maybe a combination of these will not improve the risk 
stratification that much due to redundancy. Instead a combination of a marker for 
right ventricle dysfunction and a marker for the affection of pulmonary embolisation 
on pulmonary function (e.g. exhaled NO) may improve risk stratification in the future.  
5.3. PROTECTIVE MECHANISMS OF ENDOGENOUS AND EXOGENOUS NO 
IN ACUTE PULMONARY EMBOLISM 
The present studies clearly show that endogenous NO protects against the detrimental 
effects of acute pulmonary embolism and that inhibition of the endogenous NO 
production in combination with acute pulmonary embolism severely reduces survival 
(paper I, II). Furthermore, the present work shows that exogenous NO has beneficial 
effects in acute pulmonary embolism (paper IV). Due to the widespread and diverse 
functions of NO in the body including the lung it may be hard to suggest one 
protective mechanism of endogenous and exogenous NO in acute pulmonary 
embolism. Probably it is a combination of the following: 
5.3.1. Counteraction of pulmonary hypertension 
As outlined in the introduction endogenous NO formation modulates and counteracts 
pulmonary hypertension induced by hypoxia and a thromboxane A2 mimetic in 
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rabbits (177, 228), by serotonin in cats (144) and by endothelin-1 in rats and in piglets 
(39, 134). All these three vasoconstrictors classes have been shown to be released in 
acute pulmonary embolism (201) and therefore it is likely that one protective 
mechanism of endogenous NO is counteraction of the pulmonary hypertension of 
acute pulmonary embolism. Likewise, exogenous NO, e.g. organic nitrites, will act by 
vasodilating the pulmonary circulation, thus counteracting the increased pulmonary 
vascular resistance due to the released vasoactive mediators and endothelial 
dysfunction (seen as attenuated response to acetylcholine) in the pulmonary 
vasculature (72, 201). Indeed, in the present work it is shown that PDNO and 
glycerol-NO are effective pulmonary vasodilators in thromboxane A2-induced 
pulmonary hypertension (paper III) and that PDNO effectively decreases pulmonary 
vascular resistance in acute pulmonary embolism (paper IV). In addition, PDNO 
produced vasodilation of the pulmonary circulation that led to decreased work load on 
the right heart and thus decreased oxygen consumption by the right heart (shown by 
decreased rate-pressure product, paper IV), which is beneficial in a condition 
associated with hypoxaemia.  
5.3.2. Modulation of perfusion and contractility of the right ventricle 
In humans and rabbits endogenous NO is a modulator of systemic vascular resistance 
(206) and the perfusion of vascular beds, e.g. skeletal muscle (176). Importantly 
endogenous NO is a regulator of coronary blood flow to the right ventricle at rest, in 
global hypoxia (and thus hypoxemia) and in pulmonary hypertension (136, 247). 
Acute pulmonary embolism includes hypoxemia and pulmonary hypertension; 
therefore one protective mechanism of endogenous NO which might be by regulation 
of coronary perfusion in this condition. It is also known that endogenous NO is a 
regulator of heart performance (171) and that acute NOS inhibition reduces 
myocardial oxygen consumption and myocardial contractility (198). It has been 
shown that a low dose of NO donors increased the contractility of isolated rat 
myocytes whereas a high dose of NO donors decreased the contractile response (118). 
However the actual role of NO in myocardial performance is complex and is debated 
due to conflicting results (171) and it is hard to predict the effect of exogenous NO on 
contractility. If treatment with PDNO will further increase blood flow to the right 
ventricle in a healthy laboratory animal is uncertain, but we speculate that increased 
oxygen supply to the right ventricle may be another beneficial effect of PDNO in 
acute pulmonary embolism. This effect may be important in a human suffering from 
acute pulmonary embolism with risk factors for atherosclerosis and endothelial 
dysfunction where the endothelial NO production is diminished (184, 185). One 
important finding together with this is that the treatment did not result in decreased 
systemic blood pressure, since systemic arterial blood pressure is an important 
determinant of perfusion of the right myocardium especially in pulmonary 
hypertension (237). 
5.3.3. Modulation of platelet aggregation 
Endogenous platelet-derived NO modulates platelet aggregation and inhibition of 
endogenous NO synthesis leads to enhanced aggregation of thrombocytes (187). It has 
been shown that inhibited NO production augments platelet aggregation in vivo 
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induced by adenosine diphosphate, platelet activating factor or thrombin (138). It is 
postulated that endothelial-derived NO inhibits platelet adhesion and aggregation 
whereas platelet-derived NO limits further recruitment of thrombocytes, modulates 
granule secretion, including vasoconstrictive substances such as serotonin and ADP, 
and restricts thrombus growth (155, 162). Furthermore endogenous NO may inhibit 
platelet aggregation by inhibiting exocytosis of the endothelial cells (137). Since it is 
known that platelets are activated by pulmonary emboli (40, 223), endogenous NO in 
pulmonary embolism may limit further aggregation and recruitment to the emboli and 
maybe more importantly result in decreased release of vasoconstrictive substances 
from the thrombocytes. Indeed, Emerson et al. (69) have previously shown that NO-
synthase inhibition reduces the dose of collagen+adrenalin required to induce 
thromboembolic mortality. NO donors and authentic NO inhibit platelet aggregation 
(145, 242), which may inhibit thrombin-induced Ca2+ mobilisation and the subsequent 
release of vasoconstrictive agents (e.g. serotonin) from activated platelets (109) thus 
reducing pulmonary hypertension. Therefore in addition to a direct vasodilating effect 
of PDNO in acute pulmonary embolism (paper IV), it may also decrease the 
pulmonary hypertension by inhibiting the release of vasoconstrictors.  
5.4. POTENTIAL USE OF DRUGS AFFECTING THE NO SYSTEM IN ACUTE 
PULMONARY EMBOLISM 
The present thesis work introduces the use of organic nitrites in acute pulmonary 
embolism. PDNO showed significantly beneficial effects in this study by decreasing 
and normalising the pulmonary vascular resistance (by almost 100%) and thereby 
decreasing the work for the right ventricle (paper IV). The mechanisms behind these 
effects are discussed above. No severe adverse effects were noted; systemic arterial 
blood pressure was maintained due to the relative selectivity towards the pulmonary 
circulation, the shunt fraction was unchanged, methaemoglobin remained low and 
tolerance did not develop.  
Several studies have examined the effects of supplying NO or of enhancing the effects 
of endogenous NO or a combination thereof, in acute pulmonary embolism and the 
major part of them are described in the introduction. Intravenous nitroglycerin and 
sodium nitroprusside have some beneficial effects on the pulmonary hypertension in 
acute pulmonary embolism, however their use in this condition is severely hampered 
by the systemic hypotension they induce (143). Previous studies showed that inhaled 
NO after acute pulmonary embolisation attenuates part (up to 40%) of the increase in 
pulmonary vascular resistance without systemic hypotension; however the effects on 
pulmonary gas exchange were conflicting (219). Since the initiation of this thesis 
project, it has been shown in a canine model of pulmonary microembolism that the 
NO donor diethylenetriamine/nonoate did not produce pulmonary vasodilation 
without development of severe systemic hypotension (61). Inorganic nitrite (450 nmol 
kg-1 min-1 for 15 min followed by 280 nmol kg-1 min-1 for 105 min) showed some 
beneficial effects of the pulmonary hypertension, by increasing cardiac output with no 
effects on the pulmonary arterial pressure, in dogs embolised with autologous blood 
clots (57). In pulmonary microembolism in dogs sildenafil attenuated approximately 
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50% of the increase in pulmonary vascular resistance without affecting the systemic 
arterial blood pressure (62). In another study by the same group, the beneficial effects 
of inorganic nitrite were enhanced by combined treatment with sildenafil, however 
systemic arterial blood pressure also decreased (58). These studies suggest that 
inorganic nitrite is beneficial in acute pulmonary embolism but the present data (paper 
IV) show that doses of inorganic nitrite that have hemodynamic effects also induce 
methaemoglobin, which unfortunately was not measured in the study by Dias-Junior 
et al. (58). In contrast, the dose of PDNO used in the present study (paper IV) only 
resulted in an increase in methaemoglobin by 0.3%, and future studies investigating 
the effects of inorganic nitrite should preferably include measurements of 
methaemoglobin. The present work indicates that intravenous treatment with PDNO 
produces larger effects on pulmonary vascular resistance than inhaled NO, 
demonstrating that intravenous administration of lung selective organic nitrites may 
reach larger vessels.  
Indications for NO donor treatment in acute pulmonary embolism 
Taken together, several studies including the present thesis work (paper IV) show 
beneficial effects of exogenous NO in acute pulmonary embolism. Since the majority 
of the possibly preventable deaths (i.e. diagnosed) in acute pulmonary embolism (241) 
occur in the first few hours, one indication of treatment with organic nitrites could be 
as a life-saving treatment in hemodynamically unstable patients where it is known that 
the mortality is very high (25-50%) (82). Another possible indication would be in 
hemodynamically stable patients with right ventricular dysfunction where the 
mortality is significantly higher than in patients without right ventricular dysfunction 
(124). The beneficial effects of thrombolysis on systemic and pulmonary 
hemodynamics as well as right ventricular function are significant the first days, 
whereas one week after the pulmonary embolisation, thrombolytic treatment and 
anticoagulation treatment have resulted in a similar improvement (120). Since 
thrombolysis is associated with risk of major bleeding, it would be beneficial for these 
patients to be treated with anticoagulation if the right ventricular function can be 
preserved by the use of a pulmonary vasodilator. 
5.5. MECHANISMS OF SELECTIVITY AND LOW TENDENCY FOR 
METHAEMGLOBIN FORMATION OF ORGANIC NITRITES 
In the present study it was found that the relative selectivity towards the pulmonary 
and systemic circulation respectively of different organic nitrites varied (paper III). 
By use of calculated physico-chemical descriptors of the organic nitrites it was found 
that the relative polarity of the organic nitrite molecule determined the selectivity, i.e. 
the less relative polarity of the molecule the more effects in the pulmonary circulation 
versus the systemic circulation. Furthermore the most non-polar organic nitrites 
induced methaemoglobin formation. Relative polarity can be regarded as a measure of 
lipophilicity. It is known that several measures of compound lipophilicity correlate 
well with cell membrane passage (123). Therefore it may be speculated that very non-
polar organic nitrite compounds very easily passed through the cell membrane of the 
red blood cell and therefore came in close contact with haemoglobin, directly reacted 
  43 
General Discussion 
with haemoglobin or released the NO molecule that immediately reacted with the 
haemoglobin, and produced methaemoglobin (64, 130). Less non-polar compounds 
did not penetrate the cell membrane of the red blood cells that easily and therefore did 
not produce methaemoglobin. Interestingly the half-life of free NO in blood is 
estimated to 2 ms, due to the rapid reaction with haemoglobin to form 
methemoglobin, and the rate of this reaction is solely diffusion-limited (130). This 
explains why NO gas dissolved in saline did not have hemodynamic effects other than 
those that were attributed to inorganic nitrite in the solution and it also shows that NO 
in close contact with haemoglobin will produce methaemoglobin. Therefore the 
permeability through the cell membrane of the red blood cells may determine 
tendency to methaemoglobin formation. The same reasoning might be applied to the 
endothelial cell layer in the pulmonary circulation, i.e. less polar compounds penetrate 
the endothelial cell barrier more easily and reach the smooth muscle cells in the 
pulmonary arteries and also more easily release NO which is then detected in exhaled 
gas. More polar compounds are not cleared that much in the pulmonary circulation 
and a higher concentration of the compound reaches the systemic circulation and 
therefore produces more effects on systemic arterial blood pressure. This idea agrees 
with the finding that higher doses of PDNO led to more active compound reaching the 
systemic circulation and thereby produced systemic hypotensive effects. It is 
important to emphasise that these high doses were not needed to affect the pulmonary 
hypertension. Mechanisms which have been shown to differ between organic nitrites 
are differences in efficacy in methaemoglobin formation (64), rate of hydrolysis (65), 
rate of transnitrosylation (65) and rate of enzymatic bioactivation the lung (147). Also 
the half-lifes of some organic nitrites are very short. In a study of intravenous 
infusions of isobutyl nitrite in rats, the half-life, systematic clearance and distribution 
volume of this organic nitrite were determined to 1.3 min with a monoexponential 
decline, 10 times larger than cardiac output and 5.8 l kg-1 respectively (115). An issue 
that relates to the potential adverse effects of organic nitrites and especially in our 
study where there is a surplus of un-reacted alcohol and sugar is the toxicity of the 
carrier media itself. The toxicity of 1,2-propanediol has been extensively studied as it 
is used in pharmaceutical intravenous compositions of for example vitamins and 
benzodiazepines (36, 245). The toxicity is considered very low with no mutagenic 
activity  and a dose of 1 g kg-1 day-1 is considered safe in humans (36, 245). Therefore 
due to the beneficial effects of PDNO in acute pulmonary embolism and due to the 
absence of adverse effects including toxicity, systemic hypotension and 
methaemoglobin formation, a continued development of PDNO in order to reach 
clinical use in pulmonary hypertension could be considered. 
5.6. FUTURE USE OF ORGANIC NITRITES IN DISEASES WITH 
COMPROMISED PULMONARY CIRCULATION 
The effects of these new organic nitrites, especially PDNO, should be investigated in 
other experimental models of diseases where the pulmonary circulation is 
compromised. One such model is ischemia-reperfusion of the lower body after aortic 
clamping, thus mimicking abdominal aorta aneurysm surgery. Abdominal aorta 
aneurysm is quite common in the general population and is life-threatening if 
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ruptured. Screening for abdominal aorta aneurysm reduces the mortality even though 
the post-operative mortality after elective surgery may be as high as 3% (83). The 
surgery includes aortic cross-clamping and subsequent reperfusion, which can cause 
multiple-organ failure including the lung in up to 25% of the cases (80). Several of the 
mechanisms for the lung injury are similar to acute pulmonary embolism: pulmonary 
microembolisation and the release of pro-inflammatory vasoactive mediators (79). 
Therefore treatment with organic nitrites, e.g. PDNO, could be life-saving by 
ounteracting the lung injury and perhaps also the multiple-organ failure.  c
 
General Conclusions 
6. GENERAL CONCLUSIONS 
 
1. Models of acute pulmonary embolism and for simultaneous investigation of 
endogenous and exogenous NO have been developed in the rabbit, an easily available 
and manageable laboratory animal. 
 
2. HPLC coupled to on-line nitrite reduction has been developed and is a sensitive 
method for identifying and quantifying organic and inorganic nitrites. Future use of 
this method may include analyses of body fluids in search for endogenous organic 
nitrites. 
 
3. Exhaled NO is increased in acute pulmonary embolism of different genesis, and part 
of this increase is explained by the disturbed ventilation/perfusion and probably also 
by mediator release.  
 
4. The endogenous NO system is protective both on hemodynamic parameters and on 
survival in acute pulmonary embolism of different genesis, further strengthening the 
idea that NO is a fundamental regulator of the pulmonary and cardiovascular systems.  
 
5. Organic nitrites ready for intravenous infusion can be produced by the reaction of NO 
gas with some compounds in aqueous solutions, containing a hydroxyl-group not in 
vicinity of amine or carboxyl groups.  
 
6. Organic nitrites, although one chemical entity in the sense of the O-N=O bond, is not 
a singular pharmacological entity. The selectivity towards the pulmonary and 
systemic circulation of organic nitrites is dependent on the relative polarity of the 
molecule. Methaemoglobin formation is a serious adverse effect of some organic 
nitrites whereas certain organic nitrites do not induce methaemoglobinemia.  
 
7. Certain organic nitrites administered intravenously have beneficial effects in acute 
pulmonary embolism by counteracting the pulmonary hypertension, and thus 
decrease the oxygen demand of the right heart without significant adverse effects 
such as systemic hypotension, worsening of arterial oxygenation, methemoglobin 
formation or tolerance development. 
 
8. Organic nitrites are more than 15 times more potent on a molar basis than inorganic 
nitrite in respect to hemodynamic effects, and those organic nitrites which exhibit 
little or no methemoglobin formation are potential therapeutics in situations with 
compromised pulmonary circulation, such as in pulmonary embolism and in multiple-
organ failure.  
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7. POPULÄRVETENSKAPLIG SAMMANFATTNING 
Lungembolism, d.v.s. blodproppar i lungans blodkärl, är en vanlig sjukdom i 
befolkningen, med hög dödlighet (ca 15%). Sjukdomen beror vanligtvis på att en eller 
flera blodproppar som har bildats i benens och bäckenets vener plötsligt lossnar och 
förs med blodflödet via hjärtat till lungcirkulationen (lilla kretsloppet) där de fastnar. 
En plötslig blodtrycksstegring i lungcirkulationen uppstår, vilket är påfrestande för 
högra hjärthalvan. Lungans gasutbytesfunktion försämras samtidigt och det uppstår 
syrebrist i blodet, vilket påverkar hjärtat då det behöver syrgas för att utföra sitt arbete. 
Högerhjärtat kan börja svikta vilket får en allvarlig påverkan på hela kroppens 
blodcirkulation. Tillståndet är livshotande och läkemedelsbehandling för att lösa upp 
blodproppen bör snarast påbörjas. Att sänka blodtrycket i lungcirkulationen med en 
kärlvidgande behandling för att underlätta högerhjärtats arbetsbörda skulle kunna vara 
livräddande för vissa patienter. Sjukdomen är också svårdiagnosticerad och symtomen 
liknar många andra vanliga sjukdomar. Nya markörer som på ett tydligare sätt kan 
avgöra om patienten har drabbats av lungembolism skulle vara av stort värde.  
Signalmolekylen kvävemonoxid (NO) verkar kärlvidgande i lungcirkulationen. Det 
har också föreslagits att NO är en viktig modulator för att luften i lungor på ett så 
effektivt sätt som möjligt ska möta blodflödet, d.v.s. optimera lungans 
gasutbytesfunktion. Halten NO som lungan producerar kan mätas i utandningsluften. 
Eftersom NO förefaller motverka de förändringar som uppstår vid lungembolism 
syftade det aktuella avhandlingsprojektet till att undersöka NO:s funktion vid 
lungembolism i experimentella djurmodeller.  
Först undersöktes om halten NO i utandningsluften förändras vid lungembolism. Det 
visade sig att NO kraftigt steg i den akuta fasen vilket indikerar att mätning av NO i 
utandningsluften skulle kunna vara till hjälp när diagnosen lungembolism misstänks. 
Studier där halten NO mäts i utandningsluften hos människor som drabbats av 
lungembolism bör utföras för att undersöka om halten också hos dem stiger.  
Vi fann också att den kroppsegna NO produktionen är starkt skyddande mot 
effekterna som inträffar vid lungembolism. Detta visar hur viktig signalmolekylen NO 
är för lungans funktion och indikerar att tillförsel av NO-donerande läkemedel skulle 
kunna vara av nytta vid denna sjukdom. 
Vi utvecklade därefter nya NO-donerande läkemedel som mer specifikt verkar på 
lungans blodcirkulation med minimala effekter på systemcirkulationen (stora 
kretsloppet). Blodtrycksfall i systemcirkulationen vid lungembolism kan vara skadligt 
då det kan inverka negativt på blodflödet till hjärtat. Vi fann att tillförsel av sådan 
läkemedelskandidat vid lungembolism verkade starkt kärlvidgande på lungans 
blodcirkulation och därmed sänkte lungcirkulationens blodtryck och underlättade 
högerhjärtats arbete. Detta visar att kärlvidgande behandling vid lungembolism skulle 
kunna vara av stor nytta för patienten. Framtida studier syftar till att utveckla detta 
koncept samt att undersöka effekten av lungselektiva NO-donerande läkemedel vid 
andra tillstånd där lungcirkulationen är kraftigt påverkad. 
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